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III. INTRODUCTION 
The main concept of this study was to explore molecules, which may be involved in 
the activation of the trigeminovascular system (TS) and hence in the pathomechanism of 
migraine. The findings may potentially contribute to the development of new solutions in the 
therapy of headache diseases.  
 
A. MIGRAINE 
Migraine is a common [1, 2], paroxysmal primary headache disorder. Characteristically, this 
is a highly complex, restrictive [3-5] and extremely costly [6, 7] disease, which has high 
socio-economic and personal impacts on the quality of life (workdays, school performance, 
family and social relationships).  
 
Pathomechanism 
Although there have been extensive researches in the field of migraine, the exact details of the 
pathomechanism are still unknown. Several hypotheses have been proposed to explain the 
processes of headache diseases. Although the predisposition to the development of migraine 
is presumably genetically determined, certain environmental factors (alcohol, certain foods, 
stress, hormonal changes, etc.) can trigger the emergence of headache. Factors assumed in the 
background of the mechanism of migraine include neuro-vascular alterations, neuropeptide 
release, the presence of neurogenic inflammation, plasma protein extravasation, peripheral 
and central sensitization, cortical spreading depression (CSD), a brain energy deficit and 
lesions in the white matter, as separately or simultaneously occurring phenomena. 
Since the 1990s, the central theme of migraine research has been the trigeminovascular theory, 
proposed by Moskowitz [8]. The TS provides an important pain-transmission link between 
the vascular and neuronal elements, because this is the major afferent pain pathway between 
the cranial vessels and the nuclei in the brainstem [9] (Fig. 1) [10]. Activation of the TS can 
therefore contribute to the development of migraine. 
The TS consists of the primary sensory pseudounipolar neurons whose cell bodies are located 
in the trigeminal ganglion (TRG), its terminals and the meningeal vasculature. The peripheral 
branches innervate the cranial vessels and meningeal tissues (the supratentorial dura mater, 
the dural vasculature and the pial arteries on the surface of the brain). The central fibres 
project to the area of the second-order neurons in the brainstem, the trigeminal nucleus 
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caudalis (TNC) and more caudally in the upper regions of the spinal cord (the nucleus spinalis 
nervi trigemini). The third-order neurons are located in the thalamus. 
The sensory trigeminal unit is controlled by the descending pathways from the 
monoaminergic nuclei (the nuclei raphe, the periaqueductal grey matter (PAG) and the locus 
coeruleus (LC)), referred to as migraine generators. Their exact functions are unknown, 
because the activation of these nuclei may be either a trigger or a consequence of migraine 
attacks. It is sure that elevated numbers of c-fos-immunoreactive (-ir) cells have been 
confirmed in the nucleus raphe magnus (NRM) following electrical stimulation of the TRG in 
rat [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transmitters, neuropeptides and sensitization 
Trigeminovascular activation produces a significant release of vasoactive molecules and 
various neuropeptides from the terminals of the trigeminal branches. Calcitonin gene-related 
peptide (CGRP), vasoactive intestinal peptide (VIP) and substance P (SP) can induce 
Figure 1. Trigeminovascular system (TS) 
TCC: trigeminocervical complex; PAG: periaqueductal grey matter; 
LC: locus coeruleus; NRM: nucleus raphe magnus   
Goadsby PJ. Neurol Clin. 2009;27:335-60. 
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functional changes such as vasodilatation, protein extravasation, mast cell degranulation, 
neurogenic inflammation and sensitization [12]. The co-existence of SP-, CGRP- and 
pituitary adenylate cyclase-activating polypeptide (PACAP)-ir fibres has been demonstrated 
in the region of the human TNC. Numerous SP-positive fibres have been identified in the LC, 
the NRM and the PAG, and also a few VIP fibres in the latter two structures. CGRP-ir cells in 
high number and PACAP-ir cell bodies have been found in the LC. It seems that, of the above 
molecules, the role of CGRP is the most significant in the mechanisms of migraine [13]. 
Stimulation of the TRG in laboratory animals and also in humans increases the intracranial 
blood flow in part, presumably via CGRP release [14, 15]. During migraine attacks, an 
elevated plasma CGRP level has been reported in the external jugular vein [16], but these 
results were recently disputed [17, 18]. Furthermore, an elevated CGRP concentration was 
observed in the cubital vein during nitroglycerin (NTG)-provoked headache, which returned 
to the baseline after the cessation of the pain. A correlation was detected between the CGRP 
level, the timing of the attack and the severity of the pain. The influence of CGRP in migraine 
headache is validated by the administration of triptans, which successfully ameliorate the 
attacks, the level of CGRP returning to the control [19]. 
 
Epidemiology and general features 
Epidemiological studies have revealed that the prevalence of migraine in the adult population 
in the developed countries is approximately 12%. Migraine may develop at any age and 
gender, but it is relatively common in young adult women. The diagnostic criteria of migraine 
are at least five attacks/month fulfilling the specified length of the attacks, the characteristics 
and the specific accompanying symptoms. Typically, the attacks are separated by shorter or 
longer painless intervals [20]. 
 
Types 
The 2004 guidelines of the Headache Classification Committee of the International Headache 
Society (IHS) [20] state that there are two main forms of this disease: migraine with or 
without aura. 
 
Migraine without aura (Common/simple migraine) 
This is the predominant, a clinical syndrome manifesting in recurrent attacks. The throbbing 
headache is characterized by a unilateral location, moderate or severe intensity and a lasting 
nature (4-72 hours). Routine physical activity aggravates the pain, and the attacks are 
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accompanied by specific features and associated symptoms (autonomic, eg. nausea, vomiting, 
vertigo, a feeling of weakness and shivering, and sensory, e.g. osmo-, photo- and 
phonophobia and often allodynia). Allodynia, which means an exaggerated pain reaction to a 
normally innoxious stimulus, may be highlighted, as it was examined in our study. The 
sensitization of the peripheral (TRG) and second-order (trigeminocervical complex; TCC) 
trigeminovascular neurons evokes throbbing and cephalic allodynia. The sensory input 
converges from the cephalic vasculatures, the meninges, the scalp and the facial skin. The 
activation of the third-order trigeminovascular neurons (the posterior thalamic nuclei) can be 
associated with the formation of extracephalic allodynia, which is related to the sensitivity of 
the facial and body skin [21, 22]. Additionally, migraine without aura often displays a 
menstrual relationship [23], which was also investigated in our project. 
Migraine with aura (Classic/complicated migraine) 
In migraine with aura, the episodic headache attacks and associated migraine symptoms are 
similar to those mentioned previously. However, they are usually preceded or sometimes 
accompanied by the phenomenon of aura, which is a transient, focal neurological symptom, 
lasting from minutes to an hour. Patients report the aura as a premonitory phase, occurring 
hours or days before the headache, and a headache resolution phase. They experience visual 
(scintillating scotoma and fortification spectrum) and sensory (paresthesia) symptoms and/or 
with aphasia; hyperactivity, hypoactivity, depression, a craving for particular foods, repetitive 
yawning, fatigue and neck stiffness and/or pain may also occur.  
 
Phases and symptoms 
The period of the migraine attack can be divided into 4 sections.  
a) The prodromal phase, as the early warning signs of the beginning of the attack, occurs 
several hours or even the day before the migraine. The patients usually notice unusual 
sensations and they may experience either strange energetic, excitable or depressed 
feelings, they may be irritable, they may feel thirsty or a craving for certain foods, they 
may be sleepy, with frequent yawning, or they may need to urinate more. These 
symptoms can facilitate the diagnosis of the problem as involving migraine. 
b) The second phase is typical only of aura with migraine. In this case, the patients have 
mainly strange visual, auditory and skin sensations, language problems, confusion and 
difficulties in concentration.  
c) The third phase is the headache with the accompanying symptoms mentioned above. 
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d) The last phase is the resolution or postdrome period, where the patient may feel tired or 
hung over, and they may have a mild headache, cognitive difficulties, gastrointestinal 
symptoms, mood changes and weakness. The patients generally note depression and 
malaise after an attack, though in extreme cases some people feel unusually refreshed or 
euphoric. 
 
Therapy 
In clinical practice, various drug treatments are available for the therapy of migraine. First and 
foremost, elimination of the provoking factors is the most important. Such agents include 
hormonal changes, foods, synthetic sweeteners, flavour enhancers, alcohol, sleep deprivation, 
stress, strong smells, weather changes and some drugs.  
The drug treatment of the diagnosed migraine patient involves both attack and interval 
therapy. In milder cases, general analgesics and non-steroidal inflammatory drugs together 
with antiemetics are sufficient, but in more severe cases specific antimigraine drugs are 
indispensable. Ergot alkaloid and serotonin (5-hydroxytriptamine, 5-HT) 1B/D-receptor 
agonist triptans are the most effective drugs in the abolition of migraine attacks, while β-
receptor and Ca2+-ion channel blockers, 5-HT2 anatgonists, tricyclic antidepressants and 
anticonvulsive drugs are of value as prophylactic therapy [24-26]. However, the effectiveness 
of these pharmaceuticals is not sufficient in all patients and the migraine-specific drugs 
usually have undesired side-effects. Hence, the investigation of new molecules, targets and 
markers involved in the pathomechanism of migraine is indispensible, with the development 
of effective drugs and successful therapy. 
 
Among the numerous “migraine-related” processes and substances, recent studies have 
potentially implicated the vasoactive PACAP in the pathophysiology, and hence in the future 
therapy of migraine [27, 28].  
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B. PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) 
 
Characteristics 
PACAP is a member of the VIP/secretin/glucagon neuropeptide superfamily and is 
considered to be a “brain-gut peptide“, by virtue of its widespread expression and functions in 
the human organism [29, 30].  
PACAP was discovered due to its ability to increase adenylate cyclase (AC) activity in rat 
pituitary cells, and was first isolated from the ovine hypothalamus in 1989 [31]. The gene of 
PACAP (ADCYAP1) is localized on the short arm of chromosome 18 [32]. The peptide exists 
in two biologically active amidated forms, containing 38 and 27 amino acids: PACAP-38 and 
PACAP-27 (Fig. 2). PACAP-38 is the 
predominant form, accounting for 90% 
of the total PACAP content in most 
mammalian tissues, but it is rapidly 
metabolized and its plasma elimination 
half-life is less than 5 min [33]. 
PACAP is widely distributed in the 
central nervous system [34-36], in 
peripheral organs [37], in the 
endocrine glands [38, 39], and in 
secretions from the exocrine glands 
[40], thereby functioning as a 
pleiotropic peptide [41, 42].  
It is a hypophysiotropic hormone [43], a neurotransmitter and a neuromodulator in the 
nervous system [44], and it exerts neuroprotective [45], antiapoptotic [46] and differentiation-
inducing effects in the developing nervous system [47, 48]. Furthermore, it serves important 
regulatory and protective roles in the gastrointestinal [49], cardiovascular [50-52], 
reproductive [53, 54] and respiratory systems [55]. The effects of PACAP are mediated 
through three receptors: VPAC1 (previously designated the VIP, VIP1 or PACAP type II 
receptor), VPAC2 (known as the VIP2 or PACAP type III receptor) and PAC1 (formerly 
known as the PACAP type I receptor); the latter has 1000-fold higher specific affinity for 
both forms of PACAP than for VIP [28, 56]. The binding of PACAP to its receptors induces 
two main signal transduction pathways. Through Gs- or Gq/11-protein activation, a number of 
kinases exert a variety of physiological and pathophysiological effects [28, 30]. 
Figure 2. Amino acid sequences of  
PACAP-27 and PACAP-38. 
PACAP 27 
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-
Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-
Ala-Val-Leu-NH2 
 
PACAP 38 
His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-
Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-
Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-
Lys-Asn-Lys-NH2  
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PACAP – neuropeptides, nociception, trigeminal system, migraine 
The role of PACAP in vasodilatation [57, 58] and nociceptive processes [59-65] has been 
confirmed in several studies. The presence of this peptide has been demonstrated in the 
trigeminal system [35, 66-68]. The co-localization of nociceptin and PACAP has been 
described, but their relationship is unknown. An investigation of human TRGs revealed that 
~68% of the nociceptin-positive cells contained PACAP [69]. In another study, moderately 
dense CGRP and PACAP-containing fibres were observed adjacent to numerous SP-ir fibres, 
but VIP-ir fibres were not seen in the TNC or at the cervical1-cervical2 (C1-C2) levels of the 
spinal cord [35, 70]. The co-existence of PACAP and SP has also been reported [71, 72]. 
Moreover, PACAP co-exists with CGRP in sensory ganglia and nerve plexuses of inner 
organs [73].  
The available human data point to the involvement of PACAP in the mechanisms of migraine. 
A clinical study has revealed that intravenously administered PACAP-38 induces headache in 
healthy volunteers and migraine-like attacks in patients with migraine without aura (6 h on 
average after the start of the infusion) [27], similarly to the effect of NTG in causing headache 
[74, 75]. Moreover, the decrease of the mean blood flow velocity in the middle cerebral artery 
and the increase of the diameter of the superficial temporal artery were also observed in the 
PACAP study of the migraineurs. This implies again that PACAP-38 has vasodilating effect 
and it has role in the migraine-related mechanisms and anatomical structures:  
A broad range of data suggest that PACAP is an integrator of nociceptive and sensitization 
processes, besides being involved in neurogenic inflammation [59, 61, 65, 76].  This peptide 
is present in the primary sensory neurons of the TRG [68], the parasympathetic otic and the 
sphenopalatine ganglia [77, 78]. Moreover, PACAP-38 is found in the cell bodies and nerve 
fibres of the human TNC and the upper regions of the cervical spinal cord, which suggests 
that PACAP may be closely related to the TS [13, 35]. We earlier furnished evidence for this 
hypothesis with animal experimental results. PACAP-deficient mice displayed reduced light-
aversive behaviour (photophobia), as well as decreased meningeal blood flow and c-fos 
expression in the TRG and TNC were detected relative to wild-type mice after NTG-induced 
TS activation [79].  
Based on these results it is assumed that PACAP may be an important mediator, and therefore 
a diagnostic marker of TS activation. The receptors of PACAP have been implicated as 
potential therapeutic targets in migraine pathophysiology [28]. However, there are no direct 
experimental data to confirm this theory and no clinical data are available on endogenous 
alterations in PACAP levels in relation to migraine. 
15 
 
IV. AIMS 
The general aim of our study was to determine whether there are any alterations in the 
concentration of PACAP in blood and nerve tissues in the case of TS activation and migraine 
disorder. Preclinical investigations were therefore conducted by the stimulation of the TS in 
animals in order to generate migraine-like conditions, while the specificity and relevance of 
PACAP in migraine were confirmed in our human clinical study.  
1) PRECLINICAL ANIMAL EXPERIMENTS 
Our goal was to investigate the potential peripheral and central effects of PACAP in two types 
of rat experiments, which are models of peripheral and central sensitization by different 
pathways: 
a) NTG-induced chemical stimulation  
b) Electrical stimulation of the TRG 
PACAP-38-LI and PACAP-27-LI were measured following the development of the models in 
a time-dependent manner, in the venous blood plasma (the cranial vena cava) and the 
Gasserian ganglion (TRG), indicating peripheral alterations.  
In order to evaluate the central changes in both forms of the peptide, the immunoreactivities 
were determined in the area of second-order sensory neurons (TNC), the lower spinal cord 
(C3-C4) by radioimmunoassay (RIA), and the cerebrospinal fluid (CSF) from the suboccipital 
cistern by mass spectrometry (MS). 
2) CLINICAL HUMAN INVESTIGATIONS 
It is possible to analyse the mechanisms of pain in animal models, but there is no real 
clinically relevant system with which to mimic the human specificity of headache diseases 
appropriately. Human investigations are therefore particularly important to identify the key 
mediators responsible for the development and progression of migraine. 
Based on the literature, we hypothesized that the plasma concentration of PACAP-38 
increases during migraine attacks. Our aims were therefore to reveal the potential relationship 
between the PACAP-38 level of the human plasma and the presence of migraine headache.  
RIA measurements were carried out on peripheral blood plasma samples in order to determine 
the alterations in PACAP-38-LI during the ictal and interictal periods in migraine patients in 
comparison with healthy control subjects.   
In addition, the clinical features of the disease, the plasma CGRP-like immunoreactivity 
(CGRP-LI) and the PACAP-38-LI were compared to explore possible correlations. 
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V. MATERIALS AND METHODS 
1) PRECLINICAL ANIMAL EXPERIMENTS 
Animals 
Fifty-nine young adult Sprague-Dawley rats of either sex (8-12 weeks old, 250-350 g body 
weight) were used in these studies: 28 in the NTG-induced chemical TS activation model, 20 
in the electrical TRG-stimulation model, and 11 as intact animals in the control group (Table 
1). The animals were bred and maintained under laboratory conditions on a 12-h dark 12-h 
light cycle at 22-24 °C and ~60% relative humidity in the Laboratory Animal House of the 
Department of Neurology in Szeged. Standard rat chow and tap water were available ad 
libitum.  
Groups Subgroups 
Total number of 
animals 
Control  n=11 
NTG-model 90 min (n=14) 180 min (n=14) n=28 
ES-TRG-model 
ES-TRG 90 min (n=5) 180 min (n=5) 
n=20 
Sham ES-TRG 90 min(n=5) 180 min (n=5) 
 
 
Ethics 
All experimental procedures performed in this study complied fully with the guidelines of Act 
1998/XXVIII of the Hungarian Parliament on Animal Protection and the Decree on Scientific 
Procedures in Animal Experiments (243/1988), and with the recommendations of the 
International Association for the Study of Pain [80] and the European Communities Council 
(86/609/ECC). The studies were in harmony with the Ethical Codex of Animal Experiments 
and were approved by the Ethics Committee of the Faculty of Medicine, University of 
Szeged.  
 
Models 
Chemical stimulation of the TS 
A commonly applied and well-established animal model of TS activation is the systemic 
administration of NTG. Extensive literature is available on this field regarding the 
mechanisms, the good reproducibility and the human relevance [81-85].  
Table 1. Groups of animals in both models. 
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Figure 3. NTG-injection in rat. 
The NTG has proved to be useful as an antianginal drug; however, after discovery its 
headache producing side effect was immediately noted. The sublingually applied NTG 
induces a sudden, mild intensity 1-hour lasting headache after 20-30 min, in healthy subjects 
[86], but it occurs more often in migraineurs [87]. This first phase usually relieves 
spontaneously. After a delay of approximately 4 hours the NO-induced mechanisms trigger 
typical moderate or severe throbbing attack without aura only in migraine patients, which 
requires medication. Rarely, the migraine-like headache may also occur in healthy subjects, 
which can be explained by an anamnestic data predisposing the development of migraine [75]. 
 
The effect of NTG is based on the release of nitrogen oxide (NO), which produces a rapid 
vasodilatation. The effects of NO can be attributed to the soluble guanylate cyclase that 
enhances the conversion of guanosine triphosphate (GTP) to the second messenger cyclic 
guanosine-monophosphate (cGMP). The initial steps of signalling pathway are followed by 
activation of protein kinase-G (PKG), which can phosphorylate specific proteins in the 
vascular smooth muscles. As a result the RhoA monomer G-protein is inhibited, while the 
myosin light-chain protein is activated by the myosin phosphatase. The dural arteries dilate, 
which stimulate the pain-sensitive fibres around the blood vessels [88].  
NO is an endogenous transmitter, formed during the conversion of L-arginine to citrullin on 
the action of nitric oxide synthase (NOS). The NOS molecule is one of the markers of 
trigeminal activation, since NO itself is a very unstable gaseous substance, difficult to detect. 
The constitutive, Ca2+-dependent neuronal NOS isoform (nNOS) is the most important 
enzyme from the aspect of sensory information in trigeminal pain processing. It is abundant in 
the superficial layers of the dorsal horn of the spinal cord [89-91]. The inhibition of NOS was 
showed to be able to ameliorate the symptoms of spontaneous migraine attacks [92]. 
 
Experiments 
Three groups were involved in the NTG-induced chemical 
stimulation (CS) studies. One group of 11 animals remained intact. 
In two other groups, 14 animals per group received a single i.p. 
injection of NTG (prepared from Nitrolingual Pumpspray, Pohl-
Boskamp GmbH, Germany) in a dose of 10 mg/kg (0.13 ml/100 g of 
a 7.68 mg/ml solution) to induce CS of the TS (Fig. 3).  
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In rats, NTG in the dose mentioned above, as a massive stimulus for the TS, can trigger 
physiological (arterial diameter, pulsation and blood flow [93]) and molecular (c-fos, CGRP, 
SP, nNOS and Ca2+/calmodulin-dependent protein kinase II (CaMKII) [84, 94-98]) responses 
that resemble a common manifestation of activated TS.  
In case of the intact group the CSF, blood sampling and tissue preparation followed 
immediately the anaesthesia, but in the two other groups it took place only 90 min or 180 min 
after NTG administration. The animals were anaesthetized with i.p. chloral hydrate solution 
(in a dose of 0.4 g/kg), which provided stable, deep anaesthesia. Before cupping, CSF (~150 
µl per animal) was taken from the suboccipital cistern, while blood samples (5 ml per animal) 
were taken from the right cranial vena cava into ice-cold glass tubes containing 
ethylenediaminetetraacetic acid (EDTA) (12 mg) and the protease inhibitor aprotinin 
(Gordox, 1200 IU). Following cupping different nerve structures (the TNC, spinal cord (SC) 
and TRG) were excised from the animals at the 90 or 180 min time points. In preliminary 
experiments, sampling was also carried out after 15 and 30 min (data are shown in the case of 
plasma), but in view of the absence of changes in PACAP-38-LI at these times, this was not 
done later. Blood samples were kept at 4 °C until the plasma was separated by centrifugation 
(5,000 rpm for 10 min at 4 °C). Samples were stored at -80 °C until the measurement of 
PACAP-38- and PACAP-27-LI by RIA and determination of these peptides by MS (Fig. 4.). 
 
 
  
 
 
 
 
 
Figure 4. Scheme of the NTG-model in rat. 
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Electrical stimulation of the TS 
Another possibility to develop an activated state of the TS is the electrical stimulation (ES) of 
the TRG. This is a well-described, widely used and generally certified method of TS 
activation with a broad range of stimulation parameters [99-105]. ES of the superior sagittal 
sinus can evoke a similar effect. Besides direct stimulation of the peripheral trigeminal 
afferents, ES can cause mast cell degranulation in the dura mater and the tongue. Pronounced 
neurogenic inflammation (vasodilatation and plasma protein extravasation) therefore develops 
on the brain surface. These responses can be explained by the release of inflammatory 
mediators, e.g. various vasoactive neuropeptides, which can trigger general neuronal activity 
in the area of the trigeminal complex or cause changes in blood flow [106, 107] and even 
induce structural alterations in the nerve terminals [100, 108-110].  
 
Experiments 
Five animal groups were created for these 
examinations: 11 rats served as non-stimulated 
intact animals; two groups of 5 rats each were 
followed up after sham stimulation until 90 and 180 
min, respectively; and two groups of 5 rats each 
were investigated at 90 and 180 min after ES of 
the TRG. In earlier experiments, sampling was carried out after 30 min too (data are shown in 
the case of plasma), but as there was no change in PACAP-38-LI at this time, this was not 
done later. First, the rats were deeply anaesthetized with i.p. chloral hydrate solution (in a 
dose of 0.4 g/kg) and maintained throughout the experiment. The animals were placed in a 
stereotaxic setup where the head was fixed. After removal of the scalp, the localization of the 
TRG from the bregma was measured with micromanipulators according to the Watson-
Paxinos Rat Brain Atlas (anteroposterior: 3.2 mm; mediolateral: 2.9 mm). The skull was 
drilled at the assigned point and the stimulating macroelectrode was passed into the brain to 
reach the TRG (Fig. 5). The TRG was stimulated according to the following parameters: 
duration of stimulation: 30 min; stimulation rate: 10 Hz; duration of impulse: 5 ms; current: 1 
mA; stimulation mode: continuous. 
This ES method can induce massive neuropeptide release from the pseudounipolar TRG 
neurons [111-113]. This neuropeptide depletion can be attributed to the more rapid firing of 
cells caused by the relatively high current and frequency and the long duration of the 
stimulation [114]. In cases of sham stimulation, the electrode was positioned in the same way 
bregma 
TRG 
stimulating 
electrode 
• 
Figure 5. Scheme of the ES-TRG in rat. 
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at the same location, but no current was applied. CSF, blood samples and neural tissues were 
collected, stored and analysed as described above (Fig. 6.).  
 
 
 
 
 
RIA determination of plasma, CSF and tissue PACAP-38-LI and PACAP-27-LI 
Plasma and CSF concentrations of PACAP-38 and PACAP-27 were determined with specific 
and sensitive RIA techniques developed earlier [115]. The “88111-3” PACAP-38 and the 
“88123-3” PACAP-27 antisera were raised in rabbits with synthetic peptides conjugated to 
bovine serum albumin (BSA) or thyroglobulin with glutaraldehyde or carbodiimide. The high 
specificity and C-terminal sensitivity of this antibody were confirmed by cross-reactivity 
studies: no cross-reactivity was found with PACAP-27 in the PACAP-38 assay, with PACAP-
38 in the PACAP-27 assay, or with other neuropeptides in either case. Following 
centrifugation of the blood samples (2000 rpm at 4 °C for 10 min) the peptide was extracted 
from the plasma into 3 volumes of absolute alcohol. After precipitation and a second 
centrifugation (2000 rpm at 4 °C for 10 min), the samples were dried under a nitrogen flow 
and resuspended in 300 µl assay buffer before RIA determination so as to achieve a 10 times 
Figure 6. Scheme of the ES-TRG model. 
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higher concentration for the RIA procedure [61, 115]. Brain segments (TNC, TRG and C3-C4 
regions of SC) were frozen and stored at -80 °C until further processing. The samples were 
weighed and homogenized in 1 ml ice-cold bidistilled water with a manual potter homogenizer. 
The homogenates were centrifuged at 10000 rpm for 10 min and then at 12000 rpm for another 
10 min, and 70 µl samples of the supernatants were used for RIA measurements.   
The tracers were mono-125I-labeled peptides prepared in our laboratory. Synthetic peptides 
were used as RIA standards in concentrations ranging from 0 to 1000 fmol/ml. The assay was 
prepared in 1 ml 0.05 M (pH 7.4) phosphate buffer containing 0.1 M sodium chloride, 0.25% 
(w/v) BSA and 0.05% (w/v) sodium azide. The antiserum (100 µl, 1:10000 dilutions), the 
RIA tracer (100 µl, 5000 cpm/tube) and the standard or unknown samples (100 µl) were 
measured into polypropylene tubes with the assay buffer. After incubation for 48-72 h at 4 °C, 
the antibody-bound peptide was separated from the free peptide by addition of 100 µl 
separating solution (10 g charcoal, 1 g dextran and 0.5 g commercial fat-free milk powder in 
100 ml distilled water). Following centrifugation (3000 rpm at 4 °C for 15 min), the contents 
of the tubes were gently decanted and the radioactivity of the precipitates was measured in a 
gamma counter (Gamma, type: NZ310). The PACAP-38 and PACAP-27 concentrations of 
the unknown samples were read from calibration curves. 
 
Examination of PACAP-38 and PACAP-27 in the rat plasma and CSF by MS 
Identification of PACAP-38 and PACAP-27 in the rat plasma and CSF samples in 
comparison with standard solutions was performed with matrix-assisted laser desorption 
ionization time of flight (MALDI TOF) MS. The quasimolecular ions of the PACAP-38 Na+ 
adduct (MW: 4558.7) and PACAP-27 (MW: 3147.6) or its [M+Na]+ were determined. The 
aqueous solutions of the PACAP-38 and the PACAP-27 standards and the examined samples 
were loaded onto the target plate (MTP 384 massive target T, BrukerDaltonics, Bremen, 
Germany) by mixing 1 µL of each solution with the same volume of a saturated matrix 
solution, prepared freshly every day by dissolving α-cyano-4-hydroxycinnamic acid (CHCA) 
in acetonitrile/0.1% trifluoroacetic acid (TFA) (1/2, v/v) [59]. The CSF samples were desalted 
and cleaned with 0.1% TFA solution with the use of ZipTip18 pipette tips (Millipore Kft., 
Hungary). The purified proteins and peptides were eluted directly onto the MALDI target 
plate with 3 µl of acetonitrile/0.1% TFA (50/50, v/v) solution by mixing 1 µl of the saturated 
matrix solution described above. The ions were accelerated under delayed extraction 
conditions (200 ns) in positive ion mode with an acceleration voltage of 20.00 kV; each 
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spectrum was detected in linear mode. The instrument uses a 337 nm pulsed nitrogen laser, 
model MNL-205MC (LTB Lasertechnik Berlin GmbH., Berlin, Germany). External 
calibration was performed in each case with #206195 Peptide Calibration Standards 
(BrukerDaltonics, Bremen, Germany). Protein masses were acquired in the range of 1000 to 
8000 m/z. Each spectrum was produced by accumulating data from 300 consecutive laser 
shots. The BrukerFlexControl 2.4 software was used for control of the instrument and the 
BrukerFlexAnalysis 2.4 software for spectrum evaluation. 
 
Statistical analysis 
Data are presented as mean+S.E.M. of the results on n=11-28 animals. Statistical analysis was 
performed with one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test 
with GraphPad Prism 5.0 software. Levels of probability p<0.05 were considered significant. 
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2) CLINICAL HUMAN INVESTIGATIONS  
 
Participants 
87 migraine patients with or without aura and 40 healthy control subjects were enrolled in this 
study. The migraineurs were selected in accordance with the criteria of the Headache 
Classification Committee of the International Headache Society 2004 [20]. The study groups 
were age-matched. The demographic and clinical characteristics of the patient and control 
populations are summarized in Table 2. 
A detailed questionnaire was used to compile a homogeneous group of migraineurs as 
concerns the features of their migraine disease: the duration of the migraine, the attack 
frequency, allodynia [116], the severity of pain during attacks as measured on a visual-
analogue scale (VAS). The relation of the migraine attacks to the menstrual cycle [117] and to 
the presence of other non-migraine, chronic pain disorder (lumbago, low-back pain, knee- and 
hip-joint arthrosis) was also assessed. Depression was not clinically diagnosed in any of the 
cases. Healthy volunteers serving as controls were screened for non-reported/non-treated 
headaches. Subjects (both patients and controls) who displayed any significant and serious 
non-migraine chronic disorders were excluded from the study. 
Healthy control subjects 
n=40 
Mean age (years) Gender 
36.60 ± 11.84 
♀ n=26 
♂ n=14 
 
Migraine 
patients 
n=87 
Mean 
age 
(years) 
Gender 
Type of 
migraine 
Mean 
duration 
of disease 
(years) 
Mean attack 
frequency/ 
year 
Allodynia 
n=23 
Mean 
VAS-
score 
37.91 
± 
10.17 
♀ n=79 
♂ n= 8 
MA n=18 
MO n=69 
12.99 ± 
9.61 
36.80±28.44 
0. level n=64 
1. level n= 9 
2. level n= 9 
3. level n= 5 
7.94±
1.75 
 
 
 
 
Table 2. Mean data on healthy control volunteers and 87 migraineurs (age, gender, type of 
migraine (with or without aura), disease duration (years), attack frequency, allodynia and 
VAS-score) are shown. MA: migraine with aura; MO: migraine without aura. Allodynia: 0: 
absence of allodynia; 1: mild allodynia; 2: moderate allodynia; 3: serious allodynia.   
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Study design and procedures 
The study was approved by the Ethics Committee of the Faculty of Medicine, University of 
Szeged (87/2009). All study participants gave their written informed consent, in accordance 
with the Declaration of Helsinki. There were no restrictions as regards food and drink intake. 
Blood samples were drawn from migraineurs during a migraine attack and/or in an attack-free 
period. Affected patients were asked not to start their usual attack treatment until blood 
samples had been taken. Accordingly, 80 interictal and 28 ictal samples were collected. From 
among the 87 patients, blood samples of 21 migraineurs could be collected in both periods. 
Data of the 21 migraineurs are shown in Table 3. A single blood sample was taken from each 
control. Blood samples (6 ml per subject) were taken in a sitting position during rest from the 
cubital vein and collected in ice-cold glass tubes containing the anticoagulant EDTA (12 mg) 
and the protease inhibitor aprotinin (Gordox, 1200 IU), and kept at 4 °C until centrifugation 
(2000 rpm for 10 min at 4◦C). Plasma samples were stored at −80 °C until the PACAP-38-LI- 
and CGRP-LI were measured by RIA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Demographic data on 21 migraineurs, whose samples from both the ictal and the 
interictal periods were analysed. The age, gender, type of migraine (with or without 
aura), disease duration (years), attack frequency, allodynia, VAS-score, PACAP-38-LI in 
plasma samples (fmol/ml) originating from interictal and ictal phases, the time of the 
previous attack before interictal blood sampling (days) and the duration of the present 
headache (hours) are shown for each patient. MA: migraine with aura; MO: migraine 
without aura. Allodynia: 0: absence of allodynia; 1: mild allodynia; 2: moderate 
allodynia; 3: serious allodynia 
 
 
Patient Age Gender Type of migraine 
Duration 
of disease 
(years) 
Attack 
frequency
/year 
Allodynia VAS- score 
Interictal 
PACAP-38-LI 
(fmol/ml) 
Previous 
attack 
(days 
ago) 
Ictal 
PACAP-
38-LI 
(fmol/ml) 
Duration of 
headache before 
sampling 
(hours) 
1 24 ♀ MO 3 17 0 10 24.30 9 26.50 4 
2 39 ♀ MO 26 30 0 9 20.00 2 29.16 96 
3 46 ♀ MO 18 24 0 9 19.50 7 23.90 4 
4 44 ♀ MO 30 47 3 7 18.40 9 20.90 12 
5 45 ♀ MO 2 12 0 9 26.94 6 20.40 5 
6 27 ♀ MO 14 30 2 8 20.50 6 17.00 24 
7 35 ♀ MO 20 12 0 8 27.00 6 31.20 7 
8 39 ♀ MO 30 109 2 9 21.20 10 25.90 7 
9 31 ♂ MA 10 52 0 7 24.11 7 33.21 8 
10 21 ♀ MO 5 24 0 7 20.41 7 25.18 3 
11 38 ♀ MO 2 30 0 7 22.34 5 31.81 24 
12 46 ♀ MO 10 36 0 8 26.36 7 28.05 10 
13 17 ♂ MO 10 12 0 8 23.51 10 35.28 2 
14 30 ♀ MO 10 12 1 5 26.43 7 23.30 24 
15 39 ♂ MO 10 66 0 8 27.15 1 35.28 2 
16 37 ♀ MO 9 30 0 8 25.23 7 33.70 48 
17 50 ♀ MO 14 12 0 8 21.59 21 26.92 5 
18 52 ♀ MO 14 26 3 8 22.08 5 30.71 60 
19 35 ♀ MO 25 52 0 10 25.05 1 31.69 8 
20 58 ♀ MO 15 21 0 8 27.09 7 29.18 14 
21 35 ♀ MA 6 20 2 10 29.33 20 29.67 20 
Mean 37.52   13.48 32.10  8.14 23.74 7.62 28.04 18.43 
SD 10.34   8.61 23.23  1.20 3.09 4.95 5.00 23.33 
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RIA measurements and data acquisition 
Plasma concentrations of PACAP-38 were determined with specific and sensitive RIA 
techniques developed earlier [115]. The PACAP-38 antiserum “88111-3” was raised in 
rabbits with synthetic peptides conjugated to bovine serum albumin (BSA) or thyroglobulin 
with glutaraldehyde or carbodiimide. The high specificity and C-terminal sensitivity of this 
antibody were confirmed by cross-reactivity studies, and no cross-reactivity was found with 
PACAP-27 or with other related neuropeptides in either case. Following centrifugation of the 
plasma samples (2000 rpm at 4 °C for 10 min) the peptide was extracted from the plasma into 
3 volumes of absolute alcohol. After precipitation and a second centrifugation (2000 rpm at 
4 °C for 10 min), the samples were dried under a nitrogen flow and resuspended in 300 µl of 
assay buffer before RIA determination, in order to achieve a 10-times higher concentration for 
the RIA procedure [61, 115]. The tracers were mono-125I-labelled peptides prepared in our 
laboratory. Synthetic peptides were used as RIA standards in concentrations ranging from 0 to 
1000 fmol/ml. The assay was prepared in 1 ml 0.05 M (pH 7.4) phosphate buffer containing 
0.1 M sodium chloride, 0.25% (w/v) BSA and 0.05% (w/v) sodium azide. The antiserum (100 
µl, 1:10000 dilution), the RIA tracer (100 µl, 5000 cpm/tube) and the standard or unknown 
samples (100 µl) were measured into polypropylene tubes with the assay buffer. After 
incubation for 48–72 h at 4 °C, the antibody-bound peptide was separated from the free 
peptide by the addition of 100 µl of separating solution (10 g charcoal, 1 g dextran and 0.5 g 
commercial fat-free milk powder in 100 ml of distilled water). Following centrifugation (3000 
rpm at 4 °C for 15 min), the contents of the tubes were gently decanted and the radioactivity 
of the precipitates was measured in a gamma counter (Gamma, type NZ310). The PACAP-38 
concentrations of the unknown samples were read from calibration curves. 
Plasma concentrations of CGRP were determined with specific and sensitive RIA techniques 
developed earlier [118]. 
 
Statistical analysis 
Data expressed as mean±SD if not stated otherwise. The normality of the data was tested with 
the Shapiro-Wilk test. Group comparisons were carried out with the Student’s unpaired, 
paired t-tests and the Wilcoxon-test with SPSS 17.0. Data were analysed with multivariate 
test (repeated measure ANOVA) in the case of menstruation cycle and chronic pain condition 
related to PACAP-38 level. Statistical significance was accepted at p<0.05.  
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VI. RESULTS 
1) PRECLINICAL ANIMAL EXPERIMENTS 
Changes in PACAP-38-LI in rat plasma and different brain regions in response to CS of 
the TS 
The level of PACAP-38-LI in the systemic circulation of intact, untreated rats, 18.5+3.6 
fmol/ml, was not significantly changed within the 180-min examination period by CS of the 
TS with 10 mg/kg i.p. NTG (Fig.7). PACAP-27-LI was not measurable in the rat plasma; it 
was below the detection limit of the assay even when the total peptide content was extracted 
from a volume of 4 ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RIA could reliably measure both PACAP-38-LI and PACAP-27-LI in the homogenates of 
different rat brain regions related to the trigeminal system. Their concentrations were ~5-6 
fmol/mg and ~0.4-0.6 fmol/mg wet tissue respectively, in each of the TNC, the C3-C4 
segments of the SC and the TRG. NTG injection evoked significant increases in PACAP-38-
LI at both 90 min and 180 min in the TNC, but not in the other two examined areas. The 
concentrations of PACAP-27-LI were about 10 times lower than those of PACAP-38-LI in 
Figure 7. PACAP-38-like immunoreactivity (PACAP-38-LI) determined by RIA in rat 
plasma 15, 30, 90 and 180 min after i.p. injection of 10 mg/kg nitroglycerin. Plasma 
samples of untreated intact rats served as control. Each column denotes the mean+S.E.M. 
of the results on n=11-28 animals. Significant differences were not observed with one-way 
ANOVA followed by Tukey’s post-hoc test. 
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both the TNC and the C3-C4 regions of the SC. The level of the shorter form was 
approximately half that of the longer one in the TRG. The NTG-induced alterations in 
PACAP-27-LI in each region were identical to the changes in PACAP-38-LI (Fig. 8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8. PACAP-38-like and PACAP-27-like immunoreactivities (PACAP-38-LI and 
PACAP-27-LI) determined by RIA in homogenates of (A) the trigeminal nucleus 
caudalis (TNC), (B) the C3-C4 spinal cord segments, and (C) the trigeminal ganglia 
(TRG) of the rat 90 and 180 min after 10 mg/kg i.p. nitroglycerin injection. The 
respective brain segments of untreated intact rats served as control. Each column 
denotes the mean+S.E.M. of the results on n=11-28 animals; *p<0.05, ***p<0.001 vs. 
intact control (one-way ANOVA followed by Tukey’s post-hoc test). 
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Changes in PACAP-38-LI in rat plasma and different brain regions in response to ES of 
the TS 
In contrast with what was observed on CS of the TS with NTG, ES of the right TRG led to a 
significant, ~30% elevation of the plasma PACAP-38-LI 90 min later. This elevation 
subsequently declined somewhat, but still remained significant at 180 min. Sham stimulation 
(electrode insertion without ES) did not influence the PACAP-38-LI in the systemic 
circulation (Fig. 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly to the effect of the NTG injection, electrical TRG stimulation gave rise to 
significant increases in both PACAP-38-LI and PACAP-27-LI levels in the TNC after 180 
min, whereas no change was observed in the C3-C4 and the TRG regions. No change was 
detected in the sham-stimulated group (Fig. 10).  
 
 
 
Figure 9. PACAP-38-like immunoreactivity (PACAP-38-LI) determined by RIA in the rat 
plasma 30, 90 and 180 min after electrical stimulation of the TRG (10 Hz, 1 mA, 30 min). The 
plasma samples of untreated intact rats and sham-stimulated rats served as controls. Each 
column denotes the mean+S.E.M. of the results on n=11-20; *p<0.05, ***p<0.001 vs. intact 
control; +p<0.05 vs. sham-stimulated control at the respective time (one-way ANOVA 
followed by Tukey’s post-hoc test). 
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Figure 10. PACAP-38-like and PACAP-27-like immunoreactivities (PACAP-38-LI and 
PACAP-27-LI) determined by RIA in homogenates of (A) the trigeminal nucleus caudalis 
(TNC), (B) the C3-C4 spinal cord segments, and (C) the trigeminal ganglia (TRG) of the rat 
90 and 180 min after electrical stimulation of the TRG (10 Hz, 1 mA, 30 min). The respective 
brain segments of untreated intact rats and sham-stimulated rats served as controls. Each 
column denotes the mean+S.E.M. of the results on n=11-20 animals; **p<0.01 vs. intact 
control (one-way ANOVA followed by Tukey’s post-hoc test). 
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Identification of PACAP-38 and PACAP-27 in rat plasma and CSF 
PACAP-38 was clearly identified by MS at m/z 4535.3 (PACAP-38 H+ adduct) in the intact 
rat plasma samples, but PACAP-27 was not detectable (Fig. 11C) relative to the standard 
spectra (Fig. 11A,B). However, neither form could be found in the CSF samples obtained 
from any group (Fig. 11D). RIA measurements confirmed the lack of PACAP-38-LI and 
PACAP-27-LI in the CSF (data not shown). 
 
 
  
 
  
Figure 11. Identification of PACAP-38 in (B) the standard and (C) intact rat plasma 
samples by MS at m/z 4535.3 Da, representing the average mass of the protonated 
quasimolecular ion of PACAP-38. Neither the other biologically active form, PACAP-27 
(3147.6 Da), nor its [M+Na]+ could be detected as compared to the (A) PACAP-27 
standard. Panel D is a MALDI TOF spectrum of the intact rat CSF sample in positive ion 
mode using linear detection, where the characteristic peaks of PACAP-38 (4535.3 Da) 
and/or PACAP-27 (3147.6 Da) were not observed. 
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2) CLINICAL HUMAN INVESTIGATIONS  
Differences in plasma PACAP-38-LI between migraineurs and healthy controls 
As concerns the total of 87 migraine patients (n=87), a significantly lower PACAP-38-LI was 
determined in the interictal plasma of the migraineurs (n=80; 24.60±3.59 fmol/ml) than in that 
of the healthy volunteers (n=40; 26.54±4.43 fmol/ml; Student’s unpaired t-test, p<0.011, 
t=2.578) (Fig. 12/A). However, the plasma samples from the patients during their migraine 
attacks (n=28) exhibited a significantly higher PACAP-38 concentration (27.39±4.67 
fmol/ml) as compared with the interictal samples (n=59; 24.91±3.73 fmol/ml; Student’s 
unpaired t-test, p<0.009, t=-2.676) (the interictal data of those 21 migraineurs whose plasma 
samples were collected from both periods were excluded from this analysis to avoid the 
statistical problems caused by the paired samples) (Fig. 12/B). No difference was found when 
the ictal samples were compared with those of the controls (Student’s t-test for unpaired 
comparisons, p<0.447, t=-0.765) (Fig. 12/C). 
 
 
 
 
 
  
Figure 12. PACAP-38-LI (fmol/ml) was determined by RIA in the plasma of the migraineur 
groups in comparison with those of healthy volunteers. Boxes indicate PACAP-38-LI 
(median±SD, minimum and maximum values) of healthy control subjects (n=40), and of 
migraineurs (n=87) during the interictal (n=80) and ictal periods (n=28). Significant PACAP-
38-LI decrease was observed in the interictal group vs. the control with Student’s unpaired t-
test, p<0.011 (A). Leaving out the interictal data of the paired samples, the interictal (n=59) 
vs. the ictal (n=28) group comparison showed significantly higher PACAP-38-LI during 
migraine attacks with Student’s unpaired t-test, p<0.009 (B). There were no significant 
PACAP-38-LI differences between the control and the ictal group with Student’s t-test for 
unpaired comparisons, p<0.447 (C). 
A B C 
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Association between plasma PACAP-38-LI and duration of migraine 
A mild negative correlation was found between the duration of the migraine and the interictal 
PACAP-38-LI (n=87; linear regression, p<0.044, R=-0.231) (Fig. 13). Plasma PACAP-38-LI 
did not correlate with the age, attack frequency, allodynia, and the VAS-score (ANOVA, 
linear regression, p>0.05) and differences were not found regarding the gender, hormonal 
changes and pain (Student’s unpaired t-test, p>0.05). 
 
 
  
 
 
Changes in plasma PACAP-38-LI and CGRP-LI in 21 migraineurs 
To gain insight into the changes of neuropeptide levels, we measured the plasma 
concentrations of PACAP-38 and CGRP plasma concentration in the same subject during a 
headache attack and interictally. The plasma PACAP-38-LI was significantly higher in the 
ictal period (28.04±5.00 fmol/ml) than in the interictal period (23.74±3.09 fmol/ml) (n=21; 
Student’s paired t-test, p<0.001, t=-4.134) (Fig. 14/A). 
The CGRP-LI was determined simultaneously with the PACAP-38-LI in both phases in 18 
migraineurs. Significantly higher CGRP levels were observed in the plasma samples during 
the ictal period (53.74±31.52 fmol/ml) as compared to the interictal period (39.74±27.49 
fmol/ml) (n=18; Wilcoxon-test, p<0.035) (Fig. 14/B). 
Figure 13. Interictal plasma PACAP-38-LI (fmol/ml) depending on the duration of the 
migraine disorder in the group of migraineurs (n=87). A negative correlation was observed 
with linear regression on the graph, p<0.044. 
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Figure 14. 
A: PACAP-38-LI (fmol/ml) was determined by RIA on plasma samples from migraineurs 
in both interictal and ictal periods. Plots of individual data for each patient (n=21). A 
significant difference was observed between the levels in the two phases with Student’s 
paired t-test, p<0.001. 
B: CGRP-LI (fmol/ml) was determined by RIA on plasma samples from migraineurs in 
both interictal and ictal periods. Plots of individual data for each patient (n=18). A 
significant difference was observed between the levels in the two phases with Wilcoxon-
test, p<0.035.  
The thick grey lines represent the mean values. 
A 
B 
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Associations of changes in plasma PACAP-38-LI with the menstruation cycle sensitivity 
and  chronic pain conditions in 21 migraineurs 
Changes in the plasma PACAP-38-LI proved to be influenced by 2 parameters: There was a 
significant PACAP-38-LI elevation in the ictal phase (31.01±3.32) compared to the interictal 
phase (24.18±2.52) in patients whose migraine headache was not sensitive to the menstruation 
cycle (Group 1: n=11; Student’s paired t-test, p<0.00002, t=-7.250). Meanwhile, there was no 
such significant increase during the ictal phase (24.78±4.56) compared to the interictal phase 
(23.26±3.70) in patients whose migraine headache was sensitive to the menstruation cycle 
(Group 2: n=10; Student’s paired t-test, p<0.344, t=-0.998) (Fig. 15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similar PACAP-38-LI increase was detected in the ictal phase (30.01±3.69) vs. the interictal 
phase (24.15±2.47) of patients, who did not have chronic pain-related conditions (Group 1: 
n=15; Student’s paired t-test, p<0.00005, t=-5.716). However, there was no difference in the 
ictal phase (23.13±4.64) compared to the interictal phase (22.71±4.40) in patients, who had 
Figure 15. Plasma PACAP-38-LI (fmol/ml) in the interictal and ictal periods of two 
subpopulations of 21 migraineurs, characterized on the basis of the menstruation cycle 
dependence. Group 1: menstruation cycle-independent migraineurs (n=11); group 2: 
migraine patients, whose headache was sensitive to their menstruation cycle (n=10). Each 
box represents the median±SD, minimum and maximum values of the results. A significant 
difference in PACAP-38-LI was observed between the interictal and ictal phases in group 1 
with Student’s paired t-test, p<0.00002. 
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other non-migraine, chronic pain disorders (Group 2: n=6; Student’s paired t-test, p<0.833, 
t=-0.222) (Fig. 16). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
To reveal the relationship between ictal-interictal PACAP-38 levels and menstruation cycle 
and chronic pain, repeated measure ANOVA was used. Multivariate test showed significant 
main effect of PACAP-38 measurements in different phases of the disease (F(1,19)=22.579, 
p<0.0001) and main effect of headache related to the menstruation cycle (F(1,19)=22.257, 
p<0.0001). The interaction of the two factors was also significant (F(1,19)=9.096, p<0.007). 
Similar ANOVA was carried out for identifying if ictal/interictal PACAP-38 level changes 
are influenced by concomitant chronic pain conditions. While significant main effects were 
identified by analysis (ictal/interictal: F(1,19)=11.392, p<0.003, chronic pain condition: 
F(1,19)=0.553, p<0.446) the interaction was not significant in this case (p>0.05). 
No correlations were found between the levels of peptide and age, gender, the attack 
frequency, allodynia or the VAS-score.  
Figure 16. Plasma PACAP-38-LI (fmol/ml) was characterized in the interictal and ictal 
periods of two subpopulations of 21 migraineurs, separated on the basis of chronic pain 
conditions. Group 1: patients without chronic low back pain (n=15); group 2: patients with 
simultaneous low back pain (n=6). Each box represents the median±SD, minimum and 
maximum values of the results. A significant difference in PACAP-38-LI was observed 
between the interictal and ictal phases in group 1 with Student’s paired t-test, p<0.00005. 
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VII. DISCUSSION 
According to our results the alteration of PACAP-38-concentration in the peripheral 
blood plasma is associated with the migraine disease, which was also evidenced in animal 
models of the activated TS. The role of certain neuropeptides has being investigated for a long 
time in the development of migraine, but the function of PACAP in headache disorders may 
be a new perspective for the research. 
 
1) PRECLINICAL ANIMAL EXPERIMENTS  
Numerous animal experiments [59, 60, 62, 65] and some clinical studies [27, 28] have pointed 
out the key role of PACAP in nociceptive signalling mechanisms. Although its involvement 
in migraine has recently been indicated by human data [27, 223], and its 
immunohistochemical localization has been described in the TS [35], our work provides the 
first experimental evidence that its concentration is specifically altered in the TNC and the 
plasma in response to stimulation of the TS in rat models.  
Our results support the neuropeptide theory of the development of activated TS. Both 
peripheral and central sensitizations were accompanied by PACAP-level changes in our 
models, suggesting the complexity of this neuro-vascular system. The slightly divergent 
results observed in the two models can be explained by the differences in the activation 
mechanisms. 
 
Blood plasma 
Chemical stimulation of the TS 
It is well known that NO has vasodilating effect hence the NTG administration often causes 
immediate dull headache in sensitive subjects. The delay in the action of NO triggers a typical 
attack in migraineurs, which is possibly related to the activation of trigeminal Aδ and C fibres 
leading to central sensitization at the level of TNC [89].  
In our experiment, the CS of the TS was might not strong enough to generate pronounced 
alterations in plasma PACAP-38-level. The higher PACAP-38-LI 15 min after NTG injection 
as compared with the control groups is explained by the acute and short-term effect of NO. In 
another study, we showed that the systemic blood pressure decreases in the first 10 min 
following NTG injection, after that it remains unchanged [79]. These phenomena are 
manifested in alterations in vessel wall tension, which can be one of the triggers of the 
pseudounipolar neurons of TRGs, since the intracranial vasculature is mainly innervated by 
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trigeminal nerves [119]. The initial vessel wall tension changes, as an exciter, stimulate the 
peripheral trigeminal nerve terminals, and therefore a small amount of PACAP-38 can be 
released into the systemic circulation. Later, when the blood pressure starts to become normal, 
the vessel wall tension will not change as much as earlier. It does not function as a trigger, so 
it cannot evoke PACAP-38 release.  
The other explanation of the decreasing PACAP-38-LI 30, 90 and 180 min after NTG 
injection is the short (less than 5 min) plasma elimination half-life of PACAP-38 in the blood. 
Central sensitization is generally confirmed in the NTG model, as observed in our 
experiments by the elevated PACAP-38- and PACAP-27-LI in the TNC. NTG evokes 
migraine attacks [75, 120] and develops sensitization [121] in human studies. Similarly, in 
animal experiments, NTG activates the second-order neurons and selectively elevates the 
levels of nNOS- [89], CaMKII- [122] and c-fos [123] -immunoreactivity, which are involved 
in nociception and central sensitization.	  
 
Electrical stimulation of the TS 
The ES of the TRG caused significant elevations of PACAP-38-LI in the blood plasma and 
both peptide forms in the TNC, which may be a result of PACAP release from both the 
peripheral [69, 124] and presumably the central terminals of the primary sensory neurons. 
This is in line with previous findings that capsaicin can induce PACAP release from 
peripheral sensory nerves [125]. The fact that the highest PACAP level in the circulation was 
measured 90 min after the ES is probably due to its release from the peripheral terminals of 
the activated neurons that is peaking at this time. The PACAP elevation was still significant at 
180 min, but it was tending to decrease due to the peptide depletion.  
 
Trigeminal nucleus caudalis 
Chemical stimulation of the TS 
The NTG-induced PACAP increase in the region of the TNC is likely to have an important 
role in the trigeminal activation. The fact that systemic administration of PACAP can evoke 
sensitization and migraine-like attacks in migraineurs [27] is in line with the results of our 
animal experiments. Moreover, PACAP release in the dorsal horn has been reported in other 
experimental conditions of peripheral stimulation [126-130]. The potential relationship 
between PACAP and pain is enhanced by the co-localization and functional link of the NOS 
and PACAP systems, which has been described in a variety of studies [63, 76, 131-134]. 
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Electrical stimulation of the TS  
The PACAP-38-LI increase in the plasma preceded the changes seen in the TNC after ES, 
which suggests a rapid peripheral release, followed by activation and sensitization of the 
second-order trigeminal neurons. The ES-induced TS activation is followed by enhanced 
PACAP release from the central terminals of the TRG neurons in the TNC. A similar change 
was reported in the cyclophosphamide-induced chronic cystitis model, where the expression 
of PACAP-27/38 increased significantly in the spinal segments and dorsal root ganglia (DRG) 
involved in micturition reflexes [135]. This PACAP release is also in accordance with the 
elevated PACAP-level noted after capsaicin administration into the subarachnoid space [125]. 
 
Briefly, the up-regulation of this peptide may indicate a general trigeminal activation. The 
most noteworthy result was the elevation of both PACAP-38- and PACAP-27-LI in the TNC, 
which occurred selectively after both CS and ES of the TS. We have recently reported that i.p. 
injected PACAP-38 evokes a marked photophobia, meningeal vasodilatation and an increased 
number of c-fos-positive neurons in the TNC of wild-type, but not PACAP-deficient mice 
[79]. These data are in complete agreement with our present conclusion that PACAP released 
in the TNC is responsible for central sensitization of the TS. Sensitization associated 
molecular changes restricted to the “trigeminal area” were observed in previous experiments: 
c-fos, CGRP [98, 136], nNOS-immunoreactivity in the NTG model [89], and c-fos [137], 
nNOS [111], CGRP alterations [110] following the ES of the TRG. 
 
Trigeminal ganglion 
Our experiments did not reveal significant PACAP changes of any kind in the TRG in either 
model. In a previous study PACAP-immunoreactivity was showed in a small number of nerve 
cell bodies of the human TRG, but expression changes of this peptide in the ganglia were not 
fully evaluated. Increased PACAP-levels in the sensory neurons of the rat DRG have been 
described several days after irreversible peripheral nerve damage (transection) [65] and nerve 
compression [138]. Moreover, the role of PACAP both in nociception and regeneration was 
emphasized in a sciatic nerve transection rat model, where the PACAP-immunoreactivity has 
changed in the DRG and different laminae of spinal cord compared to the control and 
transected side [139]. The lack of alteration in PACAP expression in the TRG in our 
experiments might be related to the fact that we applied acute stimulations. The short 
stimulation period and latency was not sufficient to cause substantial expression changes in 
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the ganglion. The ES method of TRG differs from the peripheral nerve damage applied in the 
studies mentioned above, but it is massive enough to cause damage and depletion of PACAP-
containing cells from the TRG. Further experiments are needed to emerge the real PACAP 
changes in the TRG and to get on to unexceptional results.      
 
Cerebrospinal fluid 
An earlier study revealed decreased somatostatin- and beta-endorphin-like immunoreactivities 
of the plasma or CSF obtained by suboccipital puncture, while the neuropeptide Y-like 
immunoreactivity did not change during the attack period in patients suffering from common 
migraine [140]. The present MS results confirmed the RIA detection of the presence of 
PACAP-38 in the rat plasma. In contrast, the presence of PACAP in the CSF was not detected 
with either the highly sensitive and specific RIA technique or MS, which suggests that 
PACAP was unable to cross the blood-CSF barrier. It is unknown that whether the barriers 
stay intact or damaged in our models. PACAP-27 was not detectable in either the plasma or 
the CSF, which might be explained by the generally lower concentration (10-100 times lower) 
of PACAP-27 in the mammalian tissues examined so far [30]. 
There is a few literature about the presence of PACAP in the CSF, however, one paper 
reported that PACAP is demonstrable in an artificial CSF perfusate in a specific rat 
experimental setup, where capsaicin was added to the perfusate [125]. In addition, a human 
study suggests that PACAP-38 could be detected in the CSF of healthy control subjects, 
moreover, its concentration in the CSF significantly increases in multiple sclerosis patients 
[141]. Nevertheless, under these conditions, disruption of the blood-CSF barrier cannot be 
excluded.  
 
Functions of PACAP in other pain conditions 
A number of investigations have demonstrated various actions of PACAP in nociceptive 
processes: intrathecally administered PACAP dose-dependently decreased the flinching of the 
hindpaw in the formalin test [65, 142]. In contrast, PACAP induced hyperalgesia after 
administration into the mouse spinal cord [60]. There is evidence that PACAP and its 
receptors can modulate the activity of spinal dorsal horn neurons in rat following a chronic 
constriction injury [126].  
The neuroregulatory functions of PAC1 receptor were demonstrated in a study, where the 
chronic nociceptive response of PAC1 receptor knock-out mice was markedly reduced in 
formalin, thermal, laser and mechanical stimulation-initiated models of inflammation [143]. 
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The inflammatory/neuropathic pain due to the effect of carrageenan and spinal nerve 
transection can be suppressed by the absence of the PACAP gene. Intrathecal administration 
of N-methyl-D-aspartic acid (NMDA) did not cause mechanical allodynia in PACAP knock-
out mice, but it was evoked by the application of PACAP and NMDA together. It suggests 
that PACAP can be the promoter of excitotoxic and nociceptive processes [76]. Nevertheless, 
the typical sensitization phenomena of migraine can be evoked by the systemic application of 
PACAP-38 in humans [27]. 
Further examinations are needed to clarify these controversial data of PACAP related to its 
pronociceptive or antinociceptive effects and peripheral or central features.   
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Figure 17. Possible theories of 
interictally decreased PACAP-38-LI. 
2) CLINICAL HUMAN INVESTIGATIONS  
Our work provided the first evidence that the plasma concentration of PACAP-38 is 
significantly lower in the interictal period of migraineurs as compared with that in healthy 
volunteers, however, the amount of peptide increases in the blood during migraine headaches. 
These results suggest that PACAP-38 might be an important mediator of the pathophysiology 
of migraine. Moreover, the different peptide levels regarding the two phases of disease 
indicate that the PACAP-38 is involved in the development of attacks. 
 
Possible mechanisms behind reduced PACAP-38-LI during interictal phase of migraine 
patients 
Since correlation was found between the interictal lower plasma concentration of PACAP-38 
and the disease duration hereby we think that the amount of PACAP-38 constantly decreases 
in the neuronal elements. Therefore diminishing peptide release and reduced plasma PACAP-
38 level can be detected during the attack-free period in the long term. The correct 
mechanisms are unknown, but we suggest that at the beginning of the ictal period a specific, 
but unknown trigger (stress, hormonal changes, foods, sleep deprivation, even more the lower 
plasma concentration of peptide, etc.) might induce PACAP-38 release from the sensory 
nerve terminals, which subsequently increases the plasma PACAP-38 level. However, the 
PACAP-38-LI elevation in the ictal period is not a definitive increase rather than return to the 
baseline, since this peptide concentration is just a little bit higher than the plasma PACAP-38 
level of healthy controls. We think that the presence of 
headache might serve to adjust the balance in the plasma 
PACAP level. It needs long term follow-up and multiple 
sampling investigations in order to determine the correct 
plasma PACAP-38 alterations and the functions of this 
peptide in migraineurs. 
The reduced peptide concentration might be explained 
indirectly in terms of brain energy deficit (an 
impairment of the cerebral and striated muscle energy 
metabolism [144, 145], elevated lactate levels [146, 
147], abnormalities of mitochondrial compartments 
[148] and imbalanced Mg2+ concentration in the 
neurons [149, 150]). It may additionally be 
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hypothesized that the low interictal peptide concentration might be associated with 
degenerative changes affecting the PACAP-releasing circuitries (cortical atrophy [151], iron 
deposition in the periaqueductal grey matter [152] and increased levels of markers indicative 
of neuronal and glial damage [153] (Fig. 17)). 
 
Possible mechanisms related to the elevated PACAP-38-LI during migraine attacks 
Among proposed mechanisms, the activation of vascular and neuronal elements of TS via 
several regulatory peptides seems to be essential in the formation of migraine. Dilation of 
meningeal vessels and sensitization of trigeminal neurons have been implicated as different 
components underlying this disease. There are some anatomical and physiological factors, 
which might be involved in the migraine-like headache induced by PACAP-38. 
 
Vascular effects of PACAP-38 related to migraine 
Some studies have approached the effects of PACAP-38 in headache from the aspect of 
vessels: 
• In 1995 Zagami and co-workers have published [154] that stimulation of the superior 
sagittal sinus causes extracranial release of PACAP.  
 
• An MRI angiographic study has revealed that PACAP-38 infusion-induced headache 
is related to significant dilatation of middle meningeal arteries (MMAs), in contrast 
with middle cerebral arteries [155]. A PAC1 receptor antagonist can influence the 
vasodilating action of PACAP-38 on pressurized MMAs. Multiple variants of the 
PAC1 receptor have been found besides the VPAC2 receptors in the rat MMAs [156]. 
However, there are some controversial results regarding the relationship of PACAP-38 
and these arteries [57, 156-158]. 
 
• There is evidence that the intracarotid infusion of PACAP-38 produces significant 
dilatation of the dural arteries in rat, which administration route has proved to be more 
effective than the intravenous [58].  
 
• Recently, the PACAP and VIP receptors were characterized by means of 
pharmacological modulators in human meningeal and coronary arteries. These 
peptides were found to have lower potency and efficacy in meningeal vasculature than 
in coronary arteries. This study concluded that processes of PACAP-38-induced 
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migraine-like headache might not involve meningeal vasodilatation rather than 
sensitization of peripheral and central sensory trigeminal fibres [57].  
• The vasodilating properties of PACAP in a small extent or indirectly can contribute to 
the development of headache, e. g. PACAP induces vascular effects mediated via 
activation of perivascular nerves [159]. The vascular effects cannot be excluded, but 
based on the literature it seems that these may be less relevant in migraine [57].  
 
Mast cell effects of PACAP-38 
PACAP-38 is more potent to sensitize trigeminal sensory fibres directly and also through 
mast cell degranulation [27, 160, 161]. It was recently reported that PACAP-38 is associated 
with mast cells, MMA dilation and migraine [162], but different PACAP fragments were also 
emphasized many times in several aspects: these peptides dose-dependently induce histamine 
[163] and serotonin release on rat peritoneal mast cells. The mechanism probably involves the 
direct activation of Gi-type proteins [164] or another PACAP receptor-independent direct 
activation of one or more G proteins, which may then activate the phopholipase-C (PLC) -
dependent signal-transduction pathway [165]. It was also found that PACAP is capable of 
releasing histamine from skin mast cells [166], moreover, the mast cell degranulation 
contributes to the development of PACAP-induced dermal oedema in mice [167].  
The reported effects of PACAP infusion regarding neurogenic inflammation and mast cell 
degranulation in relation to trigeminal activation are very poor and controversial [160]. 
Effects of different truncated PACAP and VIP fragments were tested on rat peritoneal and 
dural mast cells, which has concluded that PLC-mediated mast cell degranulation is 
implicated in PACAP-induced migraine [161]. 
 
The pleiotropic effects of PACAP might be attributable to the three kinds of receptors and the 
two main known signalling pathways. According to the literature the hypothetic mechanisms 
of vasodilation and mast cell degranulation caused by PACAP are the followings: 
 
1. In the vascular smooth muscle cells through the Gs-protein activation, PACAP 
stimulates the activity of AC, leading to increased cyclic adenosine monophosphate 
(cAMP) level. The cAMP can activate the protein kinase A (PKA), which activates 
the ATP-sensitive K+-channels by phosphorylation. Subsequently the K+ ions effuse to 
the extracellular space and the cell becomes hyperpolarised. The Ca2+ influx will give 
up through the L-type voltage-gated Ca2+-channels, which results decreased 
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intracellular Ca2+concentration and vascular relaxation. Furthermore, the cAMP can 
inhibit the myosin light-chain kinase (MLCK) and induces vasodilation [168, 169] 
(Fig. 18). 
 
2. In the mast cells via the Gq/11-protein-coupled process, it activates the β-subunit of 
PLC, which generates diacyl-glycerol (DAG) and inositol-triphosphate (IP3) from the 
phosphoinositol-diphosphate (PIP2) in the plasma membrane. The IP3 can mobilise the 
Ca2+ storages in the endoplasmatic reticulum, the DAG anchors the protein kinase C 
(PKC) to the cell membrane. The Ca2+ release can activate the PKC, which contributes 
to the secretion of histamine and other inflammatory mediators to the extracellular 
space inducing neurogenic inflammation [170-172] (Fig. 18). 
Indirectly the increased Ca2+-level can promotes the synthesis of NO, since the NOS I 
and NOS II are Ca2+-dependent enzymes, so the NO also causes vasodilation on 
another pathway [28, 173]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Different signalling pathways of PACAP in the smooth muscle cells and mast cells 
AC: adenylate cyclase; ATP: adenosine-triphosphate; Ca2+: calcium-ion; cAMP: cyclic adenosine 
monophosphate; DAG: diacyl-glycerol; ER: endoplasmatic reticulum; GDP: guanosine-diphosphate; Gq/11: 
heterotrimer G-protein subfamily; Gs: facilitating G-protein; GTP: guanosine-triphosphate; IP3: inositol 
triphosphate; IP3R: inositol triphosphate receptor; KATP: ATP-sensitive K+-channel;L-VGCC: L-type voltage-
gated Ca2+-channel; MLC20: myosin 20 kDa light chain; MLCK: myosin light chain kinase; MP: myosin 
phosphatase; P: phosphate group; PIP2: phosphoinositol-diphosphate; PKA: protein kinase A; PKC: protein 
kinase C; PLC-β: phospholipase C-β; VPAC1,2: PACAP receptor  Graph: Mészáros Á.    
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Neuronal effects of PACAP-38 related to migraine 
PACAP-38 is a sensory [68], sympathetic [77] and parasympathetic [78] neuropeptide [174], 
which is released from the nerve endings [13, 35, 68, 175] at the dural or other cranial 
compartments. It can modulate both vessels and nerve fibres through its receptors leading to 
elevated intracellular cAMP level [176]. There are several evidences that the increased cAMP 
causes sensitization and activates the trigeminal neurons [177] and meningeal nociceptors 
[178, 179], therefore induces delayed headache [180]. 
The headache-inducing action of PACAP-38 was first described in 2009. Schytz and co-
workers have demonstrated that PACAP-38 has a simple headache-evoking effect in healthy 
volunteers, but provokes severe migraine-like attacks in susceptible subjects. A decreased 
mean blood flow velocity in the middle cerebral artery and an increase in diameter of the 
superficial temporal artery were observed 20 min following the infusion [27].  
Since it is unknown that which alteration (development of headache or elevation of PACAP-
38-LI) occurs earlier, it is possible that PACAP-38 might cause a self-amplifying positive 
feedback, which can contribute to the maintenance and aggravation of headache. The 
causative role of PACAP-38 is equivocal, but its involvement is unquestioned. 
Based on similar features and 
receptors of PACAP and VIP, as 
well as the complex mechanism 
of migraine, it is likely that 
migraine cannot be related only to 
PACAP-38. This peptide can 
contribute to the evolution of 
migraine attacks in co-operation 
with other regulatory 
neuropeptides, molecules and 
enzymes, like VIP, CGRP, 5-HT, 
SP and NO. When the headache 
starts in response to specific 
triggers (environmental factors, TS activation (vasodilation, neuropeptide release, plasma 
protein extravasation), CSD, energy deficit), the presence and aggravation of pain may lead to 
the release of PACAP-38 from the nerve terminals, as a self-triggering process. This may be 
an explanation of the finding that the increase of plasma PACAP-38-LI in the ictal phases of 
migraineurs is moderate, though significant compared to the interictal period. Hereby the 
Figure 19. Possible theories of ictally increased 
PACAP-38-LI. 
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phenomenon of throbbing headache can be related to the increased PACAP-38-LI during the 
ictal phase of migraineurs found in our study. Subsequently, it would be plausible that the 
activation of second order trigeminal neurons by PACAP-38 can result in direct central 
sensitization [27] (Fig. 19). 
According to the wide distribution and pleiotropic effects of PACAP it is also certain that 
actually there are unknown receptors and signalling mechanisms of PACAP, which may have 
important functions in neurological diseases. Hereby our presumption is that the vascular and 
neuronal events caused by PACAP are not separable in the case of migraine. During attacks 
the PACAP-38 can release from both the central and peripheral terminals of the 
pseudounipolar neurons of TRG [66]. The peptide binds to its receptors and enters the 
systemic circulation. It seems, that activation of PAC1 and VPAC2 receptors can elicit 
vasodilation in the meningeal vessels, unlike the VPAC1 receptors are important in the 
vascular responses of cerebellar arteries [156]. The PAC1 receptors are also emphatic in the 
activation of second-order sensory neurons [79], which appears consistent with previous 
interpretations implicating PAC1 receptors in migraine [27, 181]. This is confirmed by the 
results that intradermal injection of PACAP-38 or VIP can elicit mild short-lasting cutaneous 
pain, increased skin blood flow, flare and wheal in healthy volunteers, which support that 
primarily the VPAC and not the PAC1 receptors mediate these alterations. It is evidenced that 
PACAP induces neurogenic inflammation, mast cell degranulation, neuronal activation and 
sensitization [27, 160]. Participation of PACAP in processes of migraine can be confirmed by 
administration of serotonin 5-HT1B and 5-HT1D receptor agonist sumatriptan, which 
attenuates the PACAP-induced MMA vasodilation and headache pain [27, 155].  
Summarized, PACAP can be involved in many aspects to promote the development and 
aggravation of severe headache attacks. 
 
Possible function of blood-brain barrier (BBB) in PACAP-related migraine disease 
In accordance with the molecular weights of PACAP-27 (3 kDa) and -38 (4.5 kDa) (Fig. 11/A, 
B), the PACAPs can penetrate the blood-brain barrier (BBB). PACAP is able to pass through 
the intact BBB [182, 183], the blood–spinal-[184, 185] and the blood–testis barrier [186]. 
However, the efficiency of PACAP transport across the BBB is dependent on the saturable 
peptide transport system [186-188]. Moreover, these mechanisms require specific transporters 
in specific brain areas [189, 190]. The hypothalamus and the hippocampus have the fastest 
uptake [189]. The accumulation of circulating peptide is limited in the brain by the brain-to-
blood efflux transporters [186, 191]. 
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Peptide carriers located at the BBB are often regulated and affected by diseases. Slower 
transport of PACAP can be observed into the whole brain, the olfactory bulb, the 
hypothalamus and the hippocampus in aged Alzheimer’s disease mice model [189]. The BBB 
transport of PACAP can alter following spinal cord injury, stroke, and cardiac arrest [184, 
185, 187].  
There are assumptions that the integrity of BBB is disrupted in migraineurs [192, 193]. 
Transient brain dysfunction, vasogenic cerebral oedema and damaged BBB can develop in 
lipopolysaccharide-induced brain injury in rats in response to the over-expression of matrix 
metalloproteinase 9 [194]. This enzyme can degrade the basal membrane, resulting in 
structural impairment of the BBB and altered plasma levels of certain molecules, which have 
been observed in patients with migraine [195-198]. The enhanced BBB permeability in 
migraine may facilitate PACAP to penetrate into the brain parenchymal elements and exert its 
central effects. From the opposite aspect, the PACAP released in the brain [30] can also 
penetrate through the BBB, and hence may be detected in the plasma. 
 
Correlation of PACAP-38-LI with the menstruation cycle and other chronic pain 
conditions in migraineurs 
Menstruation cycle 
Migraine attacks are often closely related to female hormonal changes [117]. Hence, it is 
interesting that PACAP-38-LI increases significantly during the ictal period only in those 
women whose headache is not related to the menstrual cycle. Although, the influence of 
menstruation cycle in the PACAP-38-LI changes cannot be excluded, but there is evidence 
that the plasma concentration of PACAP-38 is relatively stable and independent of the gender, 
age, food intake or female hormonal cycles in healthy subjects [40]. 
 
Chronic pain and stress 
It is well established that PACAP-38 plays an important role in a variety of other pain 
conditions [62, 199, 200]. Contrarily in our study there was no increased PACAP-38 LI in the 
ictal phase in patients with other chronic pain conditions. Moreover, we did not find any 
statistical proof of the influence of chronic pain and the alterations of PACAP-38 level. 
The role of stress might arise in the release of PACAP. This peptide may be involved in the 
hypothalamic-pituitary-adrenal (HPA) axis activation. Stress may be an inducing factor of 
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PACAP-38-release, because it was observed that the effects of different types of stressors 
were markedly ameliorated in PACAP-deficient mice [201].  
In our animal experiments the rats were anaesthetized in the ES-TRG model, so the effect of 
stress can be excluded, however, in the NTG-induced model the rats were awake.  
The influence of stress may also be excluded in the human study, because significant 
alterations were found only in the group of migraineurs without any other chronic pain 
syndrome, which condition can be perceived as a kind of stress factor. 
 
Possible relations between the PACAP-38 and CGRP in migraineurs 
CGRP is a 37-amino-acid neuropeptide, identified in 1982 [202]. It has diverse biological 
functions in the peripheral and central nervous system [203, 204]. More than 20 years ago, the 
presence of CGRP-immunoreactivity in the rat TRG [205] and the release of CGRP was 
demonstrated in the extracerebral circulation of humans and cats in response to TS activation 
[108, 206]. CGRP-containing neurons have also been detected in the human TRG [68, 207] 
and elevated plasma CGRP levels have been described in migraine [16, 17] and other types of 
primary headache [208]. CGRP caused MMA dilation was detected in normal volunteers and 
it was reversed by sumatriptan administration [209]. Moreover, an intravenous infusion of 
human alpha-CGRP causes migraine headache [180, 210] and there is a significant positive 
correlation between plasma levels of CGRP and headache severity scores in NTG-induced 
migraine attacks [87]. However, there are inconsistent results, which found increased plasma 
levels of CGRP in migraine during attack-free periods [17]. A controversial study questions 
the importance of CGRP in migraine [211]. Additionally, a study reported no changes in 
plasma CGRP-level during migraine attacks compared to the interictal period [18].  
Despite these contradictions, the importance of CGRP in migraine became firmly established 
[212]. In fact, intravenous and oral CGRP-receptor antagonists [213, 214] might also be 
effective in the treatment of migraine [215]. However, their side-effect profile, with special 
emphasis on hepatotoxicity, currently makes this drug development direction problematic 
[216-218]. Co-expression patterns were described between the CGRP and other peptides, 
molecules [13, 219]. Our results draw attention to a possible influence between the PACAP 
and CGRP systems in migraine pathogenesis [125, 220, 221]. In addition there are evidence 
that PACAP shares expression and regulation simultaneous with CGRP [27, 155, 222].  
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VIII. CONCLUSIONS 
In the animal experiments, both PACAP-38-LI and PACAP-27-LI were specifically 
elevated in the TNC in response to both the chemical and electrical stimulation of the TS. 
Furthermore, a marked elevation of PACAP-38 was detected in the systemic circulation only 
in the ES-TRG-model. The results indicate that this peptide is closely connected with the NO 
system, and PACAP might therefore play a pivotal role in nociception and the TS.  
 From the human study, it was concluded that PACAP-38 might be implicated in the 
development of migraine headache. There are associations between the migraine periods (ictal 
and interictal) and alterations in plasma PACAP-38 levels. The quantitative changes of this 
peptide are related to the disease duration, the menstruation cycle and the presence of other 
pain-related disorders. The causative role of PACAP-38 in migraine headache demands 
further studies [223]. 
These data facilitate the understanding of the mechanisms of TS activation, and 
answer certain questions relating to clinically relevant sensitization processes. Our results 
indicate the need of investigations of the role of plasma PACAP-38 as a putative biomarker in 
migraine, which might provide new perspectives as concerns the identification of a new target 
in the therapy of migraine. 
 
The relevance and potential future applications of PACAP  
PACAP seems to be an interesting and promising target understanding the actions of TS. 
Although the poor metabolic stability, the wide distribution and diverse effects of PACAP 
limit its application as a potent therapy for diseases, even so there have been attempts to 
utilize the functions of PACAP. 
A novel fusion molecule, PACAP-TAT, which contains the 11-amino acid human 
immunodeficiency virus protein TAT, endows PACAP with an enhanced ability to penetrate 
the BBB, than that of PACAP alone. The i.p. injection of PACAP-TAT induces a stronger 
inhibitory effect on food intake, which indicates the localization of protein in the brain [224]. 
It was recently demonstrated that therapeutic amounts of PACAP could be delivered to the 
brain by the intranasal administration route [190]. The occipital cortex and striatum were the 
highest uptake regions. The cyclodextrin-containing injections may therefore be useful in the 
therapeutic targeting of peptides to specific brain regions, because the various cyclodextrins 
can produce unique PACAP distribution patterns. Besides pharmacological interventions, the 
determination of PACAP plasma levels and their alterations may serve as biomarkers. 
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IX. ORIGINAL STATEMENTS OF THE THESIS 
 
Preclinical animal experiments 
1. The concentrations of PACAP-27/38 increased in the region of the brainstem 
(trigeminal nucleus caudalis) in response to both chemical and electrical stimulation of 
the trigeminovascular system in the rat.  
 
2. The concentration of PACAP-38 was elevated in the venous blood flow after electrical 
activation of the trigeminal ganglion in the rat. 
 
Clinical human investigations 
3. A significantly lower blood plasma PACAP-38 concentration was revealed in the 
interictal phase of migraineurs as compared with healthy controls.  
 
4. The lower interictal plasma PACAP-38 concentration is associated with the duration 
of migraine disease. 
 
5. A significantly higher blood plasma PACAP-38 concentration was observed in the 
ictal phase of migraineurs as compared with the attack-free period.  
 
6. The concentration of plasma PACAP-38 was significantly elevated during migraine 
attacks in those groups whose headache is not related to the menstrual cycle or who 
did not represent chronic pain conditions (low-back pain, lumbago and knee- and hip-
joint arthrosis). 
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XII. SUMMARY 
BACKGROUND 
Migraine is a common, paroxysmal primary headache disorder. Characteristically, this is a 
highly complex, restrictive and extremely costly disease, which has high socio-economic and 
personal impacts on the quality of life. Although there have been extensive researches in the 
field of migraine, the exact details of the pathomechanism remain unknown at present. 
Epidemiological studies have revealed that the prevalence of migraine in the adult population 
in the developed countries is approximately 12%. Migraine may develop at any age and 
gender, but it is relatively common in young adult women. The 2004 guidelines of the 
Headache Classification Committee of the International Headache Society (IHS) state that 
there are two main forms of this disease: migraine with or without aura. Both types can be 
characterized by interictal (attack-free) and ictal phases. The period of the migraine attack can 
be divided into 4 sections: Prodromal phase; Aura phase (in the case of migraine with aura); 
Headache phase with the accompanying symptoms; Resolution or postdrome period. In 
clinical practice, various drug treatments are available for the therapy of migraine. However, 
the effectiveness of these pharmaceuticals is not sufficient in all patients and the migraine-
specific drugs usually have undesired side-effects. Hence, the investigation of new molecules, 
targets and markers involved in the pathomechanism of migraine is indispensible, with the 
development of effective drugs and successful therapy. 
Several hypotheses have been proposed to explain the mechanisms of headache diseases. The 
activation of the trigeminovascular system (TS) and the releases of different neuropeptides 
have been confirmed in the processes of migraine. Recent studies have potentially implicated 
the vasoactive, pituitary adenylate cyclase-activating polypeptide (PACAP) in the 
pathophysiology of migraine. PACAP is a member of the VIP/secretin/glucagon neuropeptide 
superfamily and is considered to be a “brain-gut peptide“, by virtue of its widespread 
expression and function in the human organism. The role of PACAP in vasodilatation, 
nociceptive and sensitization processes as well as in the mechanisms of neurogenic 
inflammation has been confirmed in numerous studies. PACAP is present in the primary 
sensory neurons of the TRG, the parasympathetic otic and the sphenopalatine ganglia. 
Moreover, the available human data point to the involvement of PACAP in the mechanisms 
of migraine. Schytz and his co-workers demonstrated that the intravenous administration of 
PACAP-38 causes headache in healthy subjects and migraine-like attacks in migraine patients 
without aura, 6 h on average after the start of the infusion.  
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These results suggest that PACAP may be an important mediator and diagnostic marker of the 
TS activation. The receptors of PACAP have been implicated as potential therapeutic targets 
in migraine pathophysiology, but there are no direct experimental data to confirm this theory. 
Additionally, no clinical data are available on endogenous alterations in PACAP levels in 
relation to migraine. We therefore set out to examine the relationship between migraine and 
the level of expression of PACAP in animal models and also in human conditions involving 
migraine.   
AIMS 
The aim of our study was to determine whether there are any alterations in the concentration 
of PACAP in blood and nerve tissues in the case of TS activation and migraine disorder. 
Preclinical investigations were therefore conducted by the stimulation of the TS in animals in 
order to generate migraine-like conditions, while the specificity and relevance of PACAP in 
migraine were confirmed in our human clinical study.  
MATERIALS AND METHODS 
Preclinical animal experiments 
Fifty-nine young adult Sprague-Dawley rats of either sex (8-12 weeks old, 250-350 g body 
weight) were used in these studies in two different rat models of the activated TS: one 
induced by systemic nitroglycerine (NTG) injection and the other by electrical stimulation 
(ES) of the trigeminal ganglion (TRG). These are commonly applied and well-established 
animal models of TS activation. Extensive literature is available on this field regarding the 
mechanisms, the good reproducibility and the human relevance. In case of the control group 
the cerebrospinal fluid (CSF), the blood samples and the different trigeminal nerve structures 
were taken after the anaesthesia, but in the TS-activated groups the samples were excised only 
90 min or 180 min after the stimulations. PACAP-27- and PACAP-38-like 
immunoreactivities (PACAP-LI) were determined in the plasma and specific trigeminal 
components (trigeminal nucleus caudalis (TNC), cervical regions (C3-C4) of spinal cord (SC), 
TRG) by means of radioimmunoassay (RIA) and in the CSF by means of mass spectrometry.  
 
Clinical human investigations 
87 migraine patients with or without aura and 40 healthy control subjects were enrolled in this 
study. The migraineurs were selected in accordance with the criteria of the Headache 
Classification Committee of the International Headache Society 2004. The study groups were 
age-matched. A detailed questionnaire was used to compile a homogeneous group of 
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migraineurs as concerns the features of their migraine disease. Blood samples were drawn 
from healthy control subjects and migraineurs during a migraine attack and/or in an attack-
free period. There were no restrictions as regards food and drink intake. Affected patients 
were asked not to start their usual attack treatment until blood samples had been taken. From 
among the 87 patients, blood samples of 21 migraineurs could be collected in both periods. 
Plasma samples were stored at −80 °C until the PACAP-38- and calcitonin gene-related 
peptide (CGRP)-LI were measured by RIA. Additionally, we have analysed the correlations 
between the concentrations of peptides (PACAP-38, CGRP) and the features of migraine 
disease. 
In both study procedures the plasma PACAP-27/38-LI were determined with specific and 
sensitive RIA techniques developed earlier. The PACAP-38 (“88111-3”) and PACAP-27 
(“88123-3”) antisera were raised in rabbits with synthetic peptides conjugated to bovine 
serum albumin (BSA) or thyroglobulin with glutaraldehyde or carbodiimide. The high 
specificity and C-terminal sensitivity of these antibodies were confirmed by cross-reactivity 
studies. No cross-reactivity was found with each other or with other related neuropeptides in 
either case. Plasma CGRP-LI was measured with specific and sensitive RIA techniques by 
earlier published method.  
RESULTS 
Preclinical animal experiments 
In the animal experiments, the concentrations of PACAP-27 and -38 were significantly 
elevated in the TNC 90 and 180 min after the NTG-injection (p<0.05 and p<0.001) and 180 
min after the ES of the TRG (p<0.01). The plasma PACAP-38-LI was increased 90 and 180 
min following the ES (p<0.05 and p<0.001), but not in the NTG-induced model. PACAP-27 
was not present in the plasma, and the tissue concentrations of this peptide were lower than 
those of PACAP-38. The alterations in both peptides in the tissue homogenates in response to 
both TS stimulations were identical. Significant changes were not observed in the upper 
regions of the cervical SC or in the TRG in either of the models.  Neither PACAP form could 
be identified in the CSF. 
 
Clinical human investigations 
In the human study, significantly lower PACAP-38-LI was detected in the interictal plasma of 
the migraineurs as compared with the healthy control group (p<0.05). In contrast, elevated 
PACAP-38 and CGRP levels were measured in the ictal phase relative to the attack-free 
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period in the 21 migraineurs (pPACAP-38<0.001; pCGRP<0.05) and in the case of PACAP-38-LI 
in the overall population of migraineurs (p<0.01). A mild negative correlation was observed 
between the interictal PACAP-38-LI and the disease duration. 
DISCUSSION 
Preclinical animal experiments 
Our results support the neuropeptide theory of the development of activated TS. Both 
peripheral and central sensitizations were accompanied by elevated PACAP levels, suggesting 
the complexity of this neuro-vascular system. The slightly divergent results observed in the 
two models can be explained by the differences in the activation mechanisms. The up-
regulation of this peptide may indicate a general trigeminal activation. The most noteworthy 
result was the elevation of both PACAP-38- and PACAP-27-LI in the TNC, which occurred 
selectively after both CS and ES of the trigeminal system. These selective and significant 
peptide concentration changes in the brainstem nuclei suggest that the trigeminovascular 
trigger induces a marked release of PACAPs from the central terminals of the primary sensory 
neurons. It seems that ES of the TRG generates a massive TS activation. In response, PACAP 
can release from the peripheral branches, hence it enters the circulatory system and presents in 
elevated concentration in the blood. 
We have recently reported that i.p. injected PACAP-38 evokes a marked photophobia, 
meningeal vasodilatation and an increased number of c-fos-positive activated neurons in the 
TNC of wild-type, but not PACAP-deficient mice. These data are in complete agreement with 
our present conclusion that PACAP, releasing in the TNC is responsible for the central 
sensitization.  
 
Clinical human investigations 
We presume that similar mechanisms occur in migraineurs. In consequence of an unknown 
trigger, the systemic level of PACAP-38 increases. The PACAP, similar to the CGRP exerts 
its vasodilating, sensitizing effects and can contribute to the development and aggravation of 
headache. The correlation between the disease duration and the lower PACAP-38 
concentration during the attack-free period may be a consequence of the higher PACAP-38 
releases in the ictal phase, which may progressively deplete the PACAP-containing terminals.   
 
Among proposed mechanisms, the activation of vascular and neuronal elements of TS via 
several regulatory peptides seems to be essential in the formation of migraine. Dilation of 
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meningeal vessels and sensitization of trigeminal neurons have been implicated as different 
components underlying this disease. There are anatomical and physiological factors, which 
might be involved in the PACAP-38-induced migraine-like headache: PACAP-38 is a sensory, 
sympathetic and parasympathetic neuropeptide, which is released from the nerve endings at 
the dural or other cranial compartments. It can modulate both the vessels and the trigeminal 
nerve fibres (directly or through mast cell degranulation) through its receptors leading to 
elevated intracellular cyclic adenosine monophosphate (cAMP) levels. There are several 
evidences that the increased cAMP causes sensitization and activates the trigeminal neurons 
and meningeal nociceptors, therefore induces delayed headache. 
There are assumptions that the integrity of blood-brain barrier (BBB) is disrupted in 
migraineurs. The matrix metalloproteinase 9 can degrade the basal membrane, resulting in 
structural impairment of the BBB, and altered plasma levels of certain molecules that have 
been observed in patients with migraine. The enhanced BBB permeability in migraine may 
facilitate PACAP to penetrate into the brain parenchymal elements and exert its central effects. 
From the opposite aspect, the PACAP released in the brain can also penetrate through the 
BBB, and hence may be detected in the plasma. 
Although there are contradictions in the literature of CGRP, the importance of this peptide in 
migraine became firmly established. Our results draw attention to a possible influence 
between the PACAP and CGRP systems in migraine pathogenesis. In addition there are 
evidences that PACAP shares its expression and regulation simultaneously with CGRP. The 
correlations between the PACAP-38-LI and the menstruation cycle/other chronic pain 
conditions can confirm that the alterations of plasma PACAP-38 concentrations may be 
migraine specific features.   
CONCLUSION 
Our results suggest that PACAP is a special modulator of the TS. The fact that this peptide 
has an important role in the central sensitization involved in migraine-like headache is 
confirmed by the clear association between the migraine phases and the alterations in plasma 
PACAP-38 concentration in human observations. These data facilitate the understanding of 
the mechanisms of TS activation, and indicate the need for further investigations. The plasma 
PACAP-38 alterations might be a putative biomarker of migraine and provide new 
perspectives in the therapy of migraine. 
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XIII. ÖSSZEFOGLALÓ 
 
HÁTTÉR 
A migrén egy gyakori, rohamokban jelentkező primer fejfájásbetegség, mely jelentősen rontja 
a betegek életminőségét. A genetikai, kísérletes és klinikai vizsgálatok ellenére, a migrén 
pontos pathomechanizmusa máig nem tisztázott. Epidemiológiai adatok szerint a felnőtt 
populáció kb. 12 %-át érinti a betegség, mely leggyakrabban a fiatal felnőtt nőknél (20-40 év) 
jelentkezik. A migrénnek 2 fő típusa ismert: 1. aurás; 2. aura nélküli. Mindkét forma 
jellemzője az interiktális (rohammentes) és iktális (roham alatti) fázisok váltakozása. A 
migrénes rohamperiódus további szakaszokra osztható: 1. bevezető fázis (prodróma); 2. 
esetleg jelentkezhet aura; 3. fejfájás és kísérőtünetei; 4. lábadozás, felépülés 
(reconvalescencia). A fejfájások gyógyszeres intervallum és rohamterápiája sok esetben nem 
hatékony és számos nem kívánt mellékhatással rendelkezik. Ezért szükség van olyan 
kutatásokra, melyek a migrén pathomechanizmusában szerepet játszó molekulák, targetek és 
markerek azonosítását célozzák. Azok funkcióinak pontos felderítése segítséget nyújthat új, 
hatékony gyógyszerek és terápiás megoldások kifejlesztésében. 
A fejfájások kórfolyamata számos elmélettel magyarázható, azonban a trigeminális rendszer, 
az általa beidegzett érrendszer (trigeminovascularis rendszer, TR), valamint bizonyos 
neuropeptidek és neuroaktív anyagok szerepét már többször bizonyították. Az utóbbi időkben 
néhány migrénkutatás a vazoaktív, hipofízis adenilát cikláz-aktiváló polipeptid (PACAP) 
jelentőségére hívta fel a figyelmet. A PACAP a VIP/szekretin/glukagon szupercsalád tagja és 
„brain-gut peptidként” az emberi szervezetben széles körben előfordul, számos funkcióval 
rendelkezik. A PACAP-nak szerepe van a vazodilatációban, fontos integrátor a nociceptív és 
szenzitizációs mechanizmusokban, valamint a neurogén gyulladás folyamataiban. Jelen van 
többek között a trigeminális ganglion (TRG) neuronjaiban és perivascularis 
idegvégződéseiben, a paraszimpatikus ganglion oticumban és sphenopalatinumban. Egy 
2009-es klinikai vizsgált megerősítette a PACAP szerepét migrénes folyamatokban: Schytz és 
munkatársai kimutatták, hogy a 38 aminosavas peptid, a PACAP-38, intravénás infúzióban 
migrénszerű rohamokat és jelentős érválaszokat provokál migrénes betegekben, míg 
egészséges egyénekben fejfájást indukál. A PACAP tehát fontos mediátora és diagnosztikus 
markere lehet a TR aktivációjának, azonban az endogén PACAP-szint változásokról még 
keveset tudunk. Ezért vizsgálatainkban arra kerestük a választ, hogy hogyan szabályozza a 
PACAP a migrénes fejfájások kialakulását. 
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CÉLOK 
Célul tűztük ki a PACAP koncentráció-változásának vizsgálatát a vérben és a trigeminális 
rendszerrel kapcsolt agyi régiókban az aktivált TR állatmodelljeiben, valamint klinikánkon 
gondozott migrénes betegek vérmintáiban, a migrén periódusainak, jellemzőinek 
összefüggésében. 
 
ANYAGOK ÉS MÓDSZEREK 
Preklinikai állatkísérletek 
Vizsgálatainkban 59 fiatal felnőtt Sprague-Dawley patkányt (hím/nőstény; életkor: 8-12 hét; 
testsúly: 250-350 g) használtunk. Egyrészt kémiai úton szisztémás nitroglicerin injekcióval, 
másrészt az egyik oldali TRG elektromos ingerlésével 2 különböző mechanizmusú aktivált 
TR modellt alakítottunk ki, melyek jól kidolgozott, reprodukálható és humán szempontból is 
releváns rendszerek. A stimulált csoportokban a modellek kialakítását követő 90. és 180. 
percben, míg a kontroll csoport esetében az altatást követően, liquor és a vérmintát 
gyűjtöttünk, majd eltávolítottuk a különböző trigeminális idegi struktúrákat. Ezt követően a 
mintákat -80°C-on tároltuk, majd radioimmunoassay (RIA) módszerrel meghatároztuk a 
PACAP-27- és PACAP-38-immunoreaktivitást (IR) a vérplazmában és a trigeminális 
komponensekben (agytörzsi trigeminal nucleus caudalis = TNC, C3-C4 nyaki gerincvelő, 
TRG), illetve tömegspektrometria segítségével a liquorban. 
 
Klinikai humán vizsgálatok  
87 aurás és aura nélküli migrénes beteget, illetve 40 egészséges kontroll alanyt vontunk be 
tanulmányukba. A betegeket a Nemzetközi Fejfájás Társaság 2004-es kritériumrendszere 
alapján válogattuk. A csoportokat korban egyeztettük. Részletes migrén, allodynia és 
depresszió kérdőív alapján igyekeztünk homogenizálni a migrénes betegek csoportját. A 
kontroll alanyoktól egyszer, míg migrénes betegektől a rohammentes és/vagy roham alatti 
időszakban is gyűjtöttünk vérmintát. A pácienseket megkértük, hogy fejfájások idején ne 
alkalmazzanak gyógyszeres terápiát a vérvétel előtt. 21 migrénes beteg esetében mind az 
interiktális, mind az iktális periódusban történt vérvétel. A plazma mintákat −80 °C-on 
tároltuk a PACAP-38- és kalcitonin gén-rokon peptid (CGRP)-IR, RIA módszerrel történő 
meghatározásáig. Vizsgáltuk a betegség jellemzőinek és a plazma PACAP-38, CGRP 
mennyiségi változásainak összefüggéseit.  
A PACAP-27/38 méréseket egy korábban a PTE ÁOK Anatómiai és Farmakológiai 
Intézeteiben kifejlesztett, specifikus és szenzitív RIA technikával határoztuk meg. A nyúlban 
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termeltetett antiszérumok (PACAP-38, „88111-3”; PACAP-27, „88123-3”) nagy 
specificitását és C-terminális érzékenységét keresztreakciós mérésekkel igazolták. Az 
ismeretlen minták peptid koncentrációit kalibrációs görbe alapján határoztuk meg. A CGRP-
IR meghatározását korábban publikált metodika alapján végeztük. 
 
EREDMÉNYEK 
Preklinikai állatkísérletek 
Az állatkísérletekben a TNC területén szignifikánsan emelkedett PACAP-27 és -38 
koncentrációt mértünk a kémiai stimulációt követő 90. és 180. percben (p<0.05 és p<0.001), 
valamint a TRG elektromos ingerlése után 180 perccel (p<0.01). Jelentős PACAP-38-IR 
növekedést detektáltunk az elektromos stimulációt követő 90. és 180. percben (p<0.05 és 
p<0.001), ellenben a NTG-modellben ilyen nagymértékű változást nem találtunk. A 
vérplazmában a PACAP-27-et nem tudtuk kimutatni, és szöveti koncentrációja is alacsonyabb 
volt, mint a PACAP-38 esetében. A szöveti homogenizátumokban a peptidek hasonló 
arányban változtak mindkét modellben. Sem a kémiai, sem az elektromos modellben nem 
találtunk szignifikáns peptid-szint változást a TRG-ben és a C3-C4-es nyaki gerincvelői régió 
területén. A liquorban nem tudtuk kimutatni a PACAP egyik formáját sem.  
 
Klinikai humán vizsgálatok 
A humán vizsgálatokban a migrénes betegek rohammentes periódusában szignifikánsan 
alacsonyabb plazma PACAP-38-IR-t mértünk a kontroll alanyokhoz képest (p<0.05). Ezzel 
ellentétben szignifikánsan emelkedett PACAP-38 és CGRP szinteket találtunk az iktális 
fázisban az interiktálishoz viszonyítva a 21 „önkontrollos” beteg esetében (pPACAP-
38<0.001; pCGRP<0.05), valamint a vizsgált teljes migrénes populációban (p<0.01). Enyhe 
negatív korrelációt találtunk az interiktális PACAP-38 plazma szintje és a betegség 
fennállásának időtartama között. 
 
MEGBESZÉLÉS 
Preklinikai állatkísérletek 
Eredményeink alátámasztják az aktivált TR kialakulásában szerepet játszó neuropeptid-
felszabadulás elméletet. A neuro-vaszkuláris rendszer komplexitására utal, hogy 
modelljeinkben a perifériás és a centrális szenzitzáció mechanizmusait PACAP-szint 
változások kísérik. A modellek között megfigyelhető kismértékű eltérések a különböző 
aktivációs mechanizmusoknak tulajdoníthatók. A legszembetűnőbb eredmények a TNC 
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PACAP-27 és PACAP-38-IR emelkedése, melyek szelektíven jelentkeztek mind a kémiai, 
mind az elektromos ingerlés következtében. Mindez arra utal, hogy a TR aktiválódása – mely 
úgy tűnik, hogy a TRG elektromos ingerlése következtében még jelentősebb –, nagymértékű 
PACAP felszabadulást indukál az elsődleges érző neuronok perifériás és centrális 
terminálisaiból. Feltehetően ezek után belép a keringési rendszerbe, ahol emelkedett 
koncentrációban lesz jelen. Korábbi vizsgálatainkból kiderül, hogy vad típusú egerekben az ip. 
alkalmazott PACAP-38 fotofóbiát, meningeális vazodilatációt vált ki és megemeli a TNC-ben 
a c-fos pozitív, aktivált neuronok számát, ellentétben a PACAP-deficiens állatokkal szemben. 
Ezen eredmények összefüggésbe hozhatók jelen következtetéseinkkel, miszerint a TNC-ben 
felszabaduló PACAP felelős a centrális szenzitizációért, a TR aktiválódásáért.   
 
Klinikai humán vizsgálatok 
Feltételezzük, hogy hasonló folyamatok történnek a migrénes betegekben, bár az ok-okozati 
összefüggések még nem tisztázottak. Egy ismeretlen trigger következtében a PACAP-38 
szisztémás szintje megemelkedik, és a CGRP-hez hasonlóan kifejti vazodilatatív és 
szenzitizáló hatását. A mechanizmusok hozzájárulhatnak a fejfájás kialakulásához és 
súlyosbodásához. Az interiktálisan csökkent PACAP-38-szint és a betegség időtartamával 
mutatott összefüggés (kismértékű negatív korreláció) alapján felmerül, hogy a rohamok idején 
felszabaduló nagyobb mennyiségű peptid fokozatosan kiüríti a PACAP-tartalmú rostokat.  
 
Úgy tűnik, a TR neuronális és vaszkuláris elemeinek aktivációja nélkülözhetetlen a migrén 
kialakulásához. A meningeális erek dilatációja, a trigeminális neuronok szenzitizációja illetve 
hízósejt degranuláció is befolyásolhatja a PACAP-38 indukálta migrén-szerű fejfájást. A dura 
környezetében az idegvégződésekből felszabaduló PACAP-38 képes modulálni az erek és az 
idegrostok receptorain keresztül az intracelluláris cAMP szintet. Az emelkedett cAMP szint a 
trigeminális neuronok szenzitizációját, a meningeális nociceptorok aktivációját okozhatja, 
fejfájást indukálhat.  
Irodalmi adatok szerint migrénesekben csökken a vér-agy gát (BBB) integritása. 
Megfigyelték, hogy migrénesekben a megváltozott neuropeptid szintek, laktát és magnézium 
koncentrációk, valamint mitokondriális deficitek mellett, a BBB strukturáltsága is romlik. 
Ebben a matrix metalloproteináz 9, mint a bazális membránt degradáló enzimnek jelentős 
szerepe van. Tehát feltételezzük, hogy a migrénesekben fellelhető fokozott BBB 
permeabilitás elősegítheti a PACAP átjutását az agy parenchimás szöveteibe és így az 
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kifejtheti centrális hatásait. Másrészről, az agyban felszabadult PACAP is penetrálhat a BBB-
n és nagy mennyiségben átjuthat a plazmába.  
Tanulmányunk újabb bizonyítékul szolgál arra, hogy megemelkedik a CGRP plazmaszintje 
migrénes rohamok idején. Eredményeink felhívják a figyelmet arra, hogy kapcsolat lehet a 
PACAP és CGRP rendszerek között a migrén pathogenezisében, melyet más vizsgálatok is 
igazoltak. A PACAP-38-IR és a menstruációs ciklus/ krónikus fájdalom között tapasztalt 
összefüggések azt jelzik, hogy a peptid plazmakoncentrációjának változásai migrén specifikus 
jellemzők lehetnek.  
 
KÖVETKEZTETÉSEK 
Eredményeink alapján arra következtetünk, hogy a PACAP egy speciális modulátora lehet a 
TR-nek. A peptidnek szerepe lehet a szenzitizáció folyamataiban, melyet a humán 
tanulmányban megfigyelt, migrénes fázisokhoz kötött plazma PACAP-38 
koncentrációváltozások igazolhatnak. Vizsgálataink hozzájárulnak a betegség 
pathomechanizmusának részletesebb megismeréséhez, és perspektívákat kínálnak új targetek 
azonosítására a migrén terápiájában. További kutatások szükségesek a PACAP és a fájdalom 
vonatkozásában, melyek révén a PACAP egy új biomarkere lehet a fejfájásbetegségeknek. 
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XIV. APPENDIX 
